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Quality by Design principles has been applied to understand formulation and optimization 
of nano-crystalline spray-dried powders of poorly soluble drugs. The objectives of this 
research were to: 1) investigate the effect of wet media milling on nano-crystalline 
suspensions; 2) investigate the effect of spray-drying process and formulation parameters 
on nano-crystalline suspensions; 3) understand role of bulking agents during spray or 
freeze-drying of nano-crystalline suspensions; and 4) investigate the effect of different 
sized spray-dried nano-crystals on in vitro dissolution performance.  
Poorly soluble drugs were utilized to investigate the aggregation of nano-crystals during 
the spray drying process. It was determined that temperature and excipient utilized in the 
formulations plays an important role in nano-crystal aggregation. Low inlet temperature 
(preferably less than drug melting temperature) for spray drying processing and the 
addition of stabilizers/excipients with favorable or strong interaction (such as ionic or 
hydrogen bonding etc.) with the drug will provide better stability of the nano-crystals and 
thus no or minimal nano-crystal aggregation. The percent yield of spray-dried powders is 
dependent on the glass transition temperature of the formulations and/or bulking agents 
utilized. Small molecular weight bulking agents (or matrix formers) prevented nano-
crystal aggregation due to favorable interactions with the stabilizers.  
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Stabilizers with favorable or strong interaction with the drug are preferred for the stability 
of nano-crystalline suspensions but this may cause physical and chemical instability (such 
as solid-state transformation, drug degradation etc.) during high intensity wet milling 
processing.  
USP apparatus II was modified to hold dialysis sacs and this method was utilized to test 
and distinguish nano-crystalline formulations based on their size. The developed in vitro 
release testing method (or dissolution method) was able to distinguish nano-crystalline 
formulations based on size. This method can be utilized for routine quality control assays 
performed in the pharmaceutical industry and potentially for the development of IVIVC 
for these formulations.  
In conclusion, QbD (or specifically DoE) studies performed in this research are examples 
of how this approach can be utilized to understand formation and stabilization of nano-
crystalline suspensions during milling and/or drying to achieve non-aggregating stable 
nano-crystalline powders for desired in vitro and/or in vivo performance.  
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1.1. Introduction 
	  
In recent years, the number of poorly soluble (Biopharmaceutics Classification System 
class II/IV) [1] drug entities coming out of drug discovery has increased tremendously [2-
5]. These brick-like molecules demand utilization of different approaches to increase their 
solubility and hence bioavailability before reaching the market [2-5]. Poorly soluble drugs 
if not formulated appropriately may pose certain challenges such as lower than expected 
dissolution rates and solubility, as well as high local drug concentrations due to drug 
aggregate deposition. Such high local drug concentrations can cause toxic effects and thus 
decreased systemic bioavailability [9].  There are several different methods to formulate 
poorly soluble drugs (BCS class II) and improve their bioavailability such as: preparation 
of salts, and formulation in nanosuspensions, liposomes and solid dispersions. However, 
all these methods have their own disadvantages. For example, loading efficiency of poorly 
soluble drugs in liposomes is relatively low. The formation of solid dispersions is another 
approach utilized to increase drug solubility but drug loading is relatively low (up to 20-
30% drug). Crystalline nanosuspensions is another method to improve oral bioavailability, 
however although bioavailability is improved over that of coarse (micron size and above) 
particles, the crystalline nature still limits solubility.  
Crystalline drug nanosuspensions can be defined as sub-micron colloidal dispersions of 
discrete drug particles, ranging from 100-1000 nm, that have been stabilized with 
polymers, surfactants or a mixture of both polymers and surfactant. Nanoparticles can be 
obtained using either a “top-down approach” (i.e. milling/grinding of the particles to 
achieve the required size) or a “bottom-up approach” (i.e. precipitation of drug from a 
solvent to an anti-solvent system) [10]. The top-down approach is very time consuming 
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and often leads to crystalline particles whereas the bottom-up approach is less time 
consuming and often leads to amorphous particles due to fast evaporation of the solvent 
and thus precipitation of the API as amorphous particles. The advantage of amorphous 
versus crystalline nanoparticles is the considerably higher solubility, which can be as much 
as 10 to 1600 fold. However, the stability of amorphous drugs is an important issue in the 
pharmaceutical field. Amorphous systems have higher free volume or enthalpy as well as 
high Gibbs-free energy. Accordingly, these systems are unstable and tend to crystallize to 
a stable polymorph of the drug, which typically would have lower solubility. The 
crystallization time of an amorphous drug is a kinetically controlled process (which can 
vary from seconds to years) and depends on several factors such as, storage temperature 
and moisture content. Various approaches have been used to stabilize the amorphous form 
of drugs. For example, crystallization inhibitors (high Tg polymers) can be added and/or 
the formulation may be stored at low temperature (50°C below the drug Tg) and low 
moisture/humidity conditions. 
Nanosuspensions (nano-sized formulations) are known to improve the dissolution rate and 
bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs) due to 
their increased surface area to volume ratio as described by the Noyes-Whitney equation 
[11]. Increase in surface-to-volume ratio and thus dissolution rate of nanoparticles 
improves their pharmacokinetic properties in terms of: increased rate and extent of release 
and absorption; rapid onset of action; reduced side effects and improved clinical 
performance [9, 11-13]. For example, a nanosuspension of budesonide (75 – 300 nm) has 
been reported to have double the Cmax and half the Tmax compared to larger (average 4.4 
µm) suspension particles [14]. The importance of nanosuspensions to the pharmaceutical 
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industry can be judged by the fact that six formulations are already on the market and 
approximately 10 - 15 are in different stages of clinical trials [15].  However, one of the 
major concerns with nanosuspension formulations is the preservation of their physical and 
chemical stability in aqueous medium [16, 17].  Being a liquid dosage form, 
nanosuspensions are more susceptible to both physical instability (due to crystal growth 
and agglomeration) and to chemical instability (due to degradation of the active 
pharmaceutical ingredient(s)), when compared to solid dosage forms. In fact, of all the 
marketed formulations, only Megace ES is in the suspension form (nano-particulate 
suspension of megesterol acetate).  All others are prepared as nanosuspension based solid 
dosage forms, as a way to overcome instability problems.  
In order to convert nanosuspensions into solid dosage forms, the nanosuspensions must be 
dried to obtain a powder of the nanosized drug particles and this powder may then be 
processed into tablets or capsules.  Spray and freeze-drying are the most common methods 
of removing water from aqueous systems. In this proposed project, spray drying will be 
used as a means to obtain a dry powder because of its simplicity, versatility and low cost 
of operation. However, any material undergoing a drying process experiences a lot of 
stress.  In the case of spray drying the material experiences thermal stress, and in the case 
of freeze-drying the material experiences freezing stress, both of which may affect product 
performance [17, 18]. In addition, the drying process brings about concentration of the 
originally dispersed and dissolved materials and this may adversely affect both the 
physical and chemical stability of the formulation. For example, reduction in the solvent 
volume can lead to a decrease in the solubility of the surfactant or stabilizer, resulting in 
precipitation and rendering these unavailable for protection of the nanoparticles against 
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aggregation. In the case of drying of nanocrystals the problem of aggregation and 
agglomeration is compounded due to the inherent thermodynamic instability of these 
systems resulting from their large surface area and high interfacial tension. Strong 
aggregation/agglomeration of the particles will reverse the advantage of rapid dissolution, 
which is central to nanosuspension formulations. There are few reports [16-21], which deal 
with drying of nanosuspensions, but no exhaustive study has been undertaken to 
understand the process of drying of nanosuspensions. 
 
1.2. Objectives 
	  
The objectives of this research are to: 1) investigate the effect of wet media milling process 
and formulation parameters on the size of nano-crystalline suspensions; 2) investigate the 
effect of spray drying process and formulation parameters on the aggregation behavior of 
nanosuspensions; 3) understand the mechanism of bulking agents such as, sugars in their 
ability to prevent aggregation of nano-crystals during spray drying; 4) investigate the 
effect of different sized spray-dried nano-crystals on in vitro dissolution. Such information 
will help in elucidating factors that contribute to improved shelf-life stability of nano-
crystalline formulations. 
 
1.3. Specific Aims 
The following specific aims were developed to achieve the objectives mentioned above: 
 
Specific Aim I: (Chapter 2) 
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Quality by Design Approach to Spray Drying Processing of Crystalline Nanosuspensions 
Specific Aim II: (Chapter 3) 
Formulation Parameters of Crystalline Nanosuspensions on Spray Drying Processing: A 
DoE Approach 
Specific Aim III: (Chapter 4) 
Bulking Agents to Prevent Nano-crystal Aggregation During Spray or Freeze Drying  
Specific Aim IV: (Chapter 5) 
Wet Milling Induced Physical and Chemical Instabilities of Naproxen Nano-Crystalline 
Suspensions 
Specific Aim V: (Chapter 6) 
Optimization and Dissolution Performance of Spray-Dried Naproxen Nano-Crystals 
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Chapter 2 
	  
	  
	  
	  
Quality by Design Approach to Spray Drying Processing of Crystalline 
Nanosuspensions 
 
 
 
 
Abstract 
Quality by Design (QbD) principles were explored to understand spray drying process for 
the conversion of liquid nanosuspensions into solid nano-crystalline dry powders using 
indomethacin as a model drug. The effects of critical process variables: inlet temperature, 
flow and aspiration rates on critical quality attributes (CQAs): particle size, moisture 
content, percent yield and crystallinity were investigated employing a full factorial design. 
A central cubic design was employed to generate the response surface for particle size and 
percent yield. Multiple linear regression analysis and ANOVA were employed to identify 
and estimate the effect of critical parameters, establish their relationship with CQAs, create 
design space and model the spray drying process. Inlet temperature was identified as the 
only significant factor (p value <0.05) to affect dry powder particle size. Higher inlet 
temperatures caused drug surface melting and hence aggregation of the dried nano-
crystalline powders. Aspiration and flow rates were identified as significant factors 
affecting yield (p value <0.05). Higher yields were obtained at higher aspiration and lower 
flow rates. All formulations had less that 3% w/w moisture content. Formulations dried at 
higher inlet temperatures had lower moisture compared to those dried at lower inlet  
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2.1. Introduction 
In recent years, the number of poorly soluble drug entities (Biopharmaceutics 
Classification System, BCS class II/IV) [1] coming out of drug discovery has increased 
significantly [2-5]. These brick-like molecules demand utilization of different approaches 
to increase their solubility and/or dissolution rate and thus oral bioavailability [6-8]. Poorly 
soluble drugs, if not formulated appropriately, may pose certain challenges such as high 
local drug concentrations due to drug aggregate deposition. Such high local drug 
concentrations can lead to toxicity [9].  Several different approaches can be utilized to 
formulate poorly soluble drugs (BCS class II/IV) and improve their bioavailability such as 
preparation of salts, liposomes and solid dispersions etc. However, these methods have 
their own shortcomings. For example, it is not possible to make stable crystalline soluble 
salts of all the poorly soluble drugs. The loading efficiency of poorly soluble drugs in 
liposomes is relatively low. Moreover, the drug loading in solid dispersions is relatively 
low and the physical stability can be an issue.  
Crystalline nanosuspensions can be an attractive alternative to improve solubility, 
dissolution rate, and oral bioavailability of poorly soluble drugs. Crystalline 
nanosuspensions can be defined as sub-micron colloidal drug dispersions of discrete drug 
crystals, ranging from 100 - 1000 nm. The nanosuspensions are stabilized with polymers, 
surfactants or a mixture of both. Nano-crystals can be obtained using either a “top-down 
approach” (i.e. milling/grinding of the drug crystals to achieve the required size) or a 
“bottom-up approach” (i.e. precipitation of drug from a good solvent to an anti-solvent 
system) [10]. Crystalline nanosuspensions are known to improve the dissolution rate and 
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bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs) due to 
their increased surface area-to-volume ratio [11]. Increase in surface-to-volume ratio and 
thus dissolution rate of nano-crystals improves their biopharmaceutical properties in terms 
of: increased rate and extent of release and absorption; rapid onset of action; reduced side 
effects and improved clinical performance [9, 11-13]. For example, a nanosuspension of 
budesonide (75 – 300 nm) has been reported to have double the Cmax and half the Tmax 
compared to larger (average 4.4 µm) suspension particles [14]. The importance of 
nanosuspensions in pharmaceutical dosage forms is evident from the presence of several 
commercially available drug products, and yet several more in clinical trials. [15].  One of 
the major challenges with formulation of nanosuspensions is the preservation of their 
physical and chemical stability in aqueous medium [16, 17].  Nanosuspensions are 
susceptible to both physical instability (crystal growth and agglomeration) and chemical 
instability (degradation) compared to solids. 
In order to convert crystalline nanosuspensions into solid dosage forms, the 
nanosuspensions must be dried to solids. These nano-crystalline solids may then be 
processed into capsules. Spray and freeze-drying are the most commonly utilized to dry 
nanosuspensions. However, any material undergoing a drying process experiences 
significant stress. In the case of spray drying, the material experiences thermal stress, and 
in the case of freeze-drying the material experiences freezing stress, both of which may 
affect product quality attributes [17, 18]. For example, reduction in the solvent volume can 
lead to a decrease in the solubility of the surfactant or stabilizer, resulting in precipitation 
and rendering these unavailable for protection of the nanoparticles against aggregation. A 
few published reports [16-21] deal with nanosuspensions drying, but no exhaustive study 
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has been conducted to understand the process. The current study focuses on, spray drying 
as a means of obtaining dry nano-crystalline powders. The spray drying process is most 
practical in terms of its simplicity, versatility, low production cost and industrial 
applicability [22]. 
Quality by Design (or specifically Design of Experiment, DoE) is a versatile approach to 
understand the effect of critical process parameters and to optimize process conditions [23, 
24]. DoE helps in identification of critical versus non-critical parameters affecting product 
quality attributes. Furthermore, the results of DoE afford to quantify any interactions 
between critical parameters on the responses (quality attributes). DoE can also be utilized 
for the prediction of the desired quality attributes within the design space.  
A full factorial design was employed to understand the process as well as any interactions 
between the critical factors involved in the spray drying process. The critical process 
conditions investigated were: solvent flow rate (or feed rate), inlet temperature and 
aspiration rate. The particle size (as Z-average), moisture content, percent yield and 
crystallinity were investigated as responses. In addition, a response surface study (RSM) 
was conducted to obtain a predictive model for the yield and nano-crystals aggregation 
during the spray drying process. Data analysis was performed using ANOVA and 
multifactor analysis to: 1) elucidate interactions between critical variables; 2) establish the 
rank order of the critical variables; and 3) provide a predictive model for nano-crystalline 
suspension spray drying. To the best of our knowledge, there has been no previous quality 
by design (or specifically DoE) study that has addressed the process of spray drying of 
crystalline nanosuspensions. 
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2.2. Materials  
	  
Indomethacin USP (γ polymorph) was purchased from PCCA (Houston, TX). Dowfax 2A1 
(alkyldiphenyloxide disulfonate) was generously gifted by Dow Chemical Company 
(Midland, MI). HPLC grade acetonitrile (ACROS chemicals) was purchased form Fisher 
Scientific (Pittsburgh, PA). Hermetic pans and lids were purchased from TA instruments.  
	  
	  
	  
2.3. Methods 
	  
2.3.1. Preparation of crystalline nanosuspensions 
The required amount (1% w/w) of indomethacin was dispersed in 100 ml of 0.5% w/v 
aqueous stabilizer solution (Dowfax 2A1) using a stirrer to form a macro-suspension of the 
drug. Particle size reduction was carried out by processing 100 ml of macro-suspensions 
through a Microfluidizer model 110Y (Microfluidics, Newton, MA) at 19,000 psi for 
90 min. The bulk temperature of the suspensions was maintained below 25°C during 
processing.  
2.3.2. Spray drying of nanosuspensions 
Indomethacin nanosuspension formulations were spray dried using a lab scale Buchi spray 
dryer B-190. Briefly, the spray dryer was pre-conditioned at the required setting of spray 
gas flow or airflow, aspiration rate, flow rate (or feed rate), and inlet temperature using 
distilled water. Once the spray dryer was equilibrated, 100 ml of the prepared nano-
crystalline suspension (1% w/v) formulation was pumped into the drying chamber using a 
peristaltic pump (through 0.5 mm nozzle). Nano-crystalline suspension formulations were 
spray dried at different feed rates, temperatures and aspirator settings. Spray gas 
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(atomizing air) was maintained at 40 mm Hg (the air flow was approximately 600 l/hour) 
for all the formulations. The dried samples were removed from the collection chamber 
using a plastic scraper and evaluated for percent yield, moisture content, particle size and 
polymorphic changes, if any. 
	  
	  
2.3.3. Powder X-ray diffraction (PXRD) 
PXRD (powder X-ray diffraction) was used to study the crystallinity of the dried samples. 
X-ray diffraction patterns were obtained using an X-ray diffractometer (Model D5005, 
Bruker AXS Inc., Madison, WI) using Cu-kα radiation, a voltage of 40 kV, and a current 
of 40 mA. All the scans were performed at a scan rate of 2°/minute with steps of 0.02° 
from 5° to 50° 2θ angle.  
2.3.4. Differential scanning calorimetry (DSC) 
DSC was performed using a TA Q1000 calorimeter (TA instruments, New Castle, DE, 
USA) equipped with a refrigerated cooling accessory. The instrument was calibrated for 
enthalpy and heat capacity using indium and sapphire, respectively. Approximately 5-10 
mg spray dried samples were sealed in hermetic pans and analyzed. The heating rate was 
maintained at 5°C/min from room temperature to 180°C. Nitrogen gas was used for 
purging at a flow rate of 50 ml/min. Data were analyzed using TA universal analysis 
software. 
2.3.5. Determination of percent yield 
For calculation of percent yield, the drug amount in liquid and spray-dried nanosuspension 
formulations were determined using an HPLC-UV method (as described below). Briefly, 
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the nano-crystalline suspension formulations were dissolved in the mobile phase and this 
solution was used to quantify the drug amount. The formula used for calculation of % yield 
was: 
   Equation 2.1 
Note: Drug mass in and out represents, the total amount of drug (in nanosuspensions) that 
was spray dried and that was recovered (dried powder), respectively. 
 
2.3.6. HPLC-UV method 
The standard curve of indomethacin was generated using a Perkin-Elmer HPLC system 
(series 200) connected to a UV-Vis detector (Perkin-Elmer 785). The amount of 
indomethacin was quantified using a C-18 Zorbax® column (Waters Corporation, USA) 
and the mobile phase was a mixture of two phases (A/B) at a 50:50 v/v ratio. Phase A was 
a mixture of water and phosphoric acid (0.2% v/v) and phase B was acetonitrile. The flow 
rate was maintained at 1.3 ml/min and the UV absorbance was measured at 237 nm. 
Various dilutions were made in the mobile phase to prepare a standard curve. The 
concentration range for linearity was 0.005 mg/ml to 0.2 mg/ml with a R2 value of 0.9999.  
2.3.7. Moisture Determination 
The spray-dried powder (approximately 10 mg) was dissolved in sieve-dried methanol (1 
ml). 500 µl of this drug-methanol solution was used for Karl Fisher analysis. Samples were 
injected into the titrimeter using a 1 ml syringe attached to a 22-gauge needle.  The 
% Yield = Drug Mass Out ×
100
Drug Mass In
%!
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moisture content was reported as weight percent.  
2.3.8. Particle size measurement 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments) to determine the Z-average (at 90° scattering angle) and PDI of the 
nanosuspensions before and after spray drying. Briefly, the spray-dried powders were 
suspended in saturated and filtered (0.2 µm membrane filter) solutions of indomethacin in 
30% glycerin solution to avoid any discrepancy from dissolution of nano-particles during 
measurement. The viscosity of this dispersant solution was measured using a Brookfield 
viscometer (Model DV-III) and was used to calculate the particle size of the 
nanosuspensions. Each sample was analyzed in triplicate and the results were reported as 
the mean value of these runs. 
2.3.9. Design of Experiment 
Based on our preliminary experiments (data not shown), it was determined that the 
aspirator, inlet temperature and flow (or feed) rate were important spray drying process 
variables.  All indomethacin nanosuspension formulations (100 ml) were prepared using a 
microfluidizer (Microfluidics®) according to our previous published method [25]. The 
bulk temperature of the formulations during particle size reduction was maintained below 
25°C to avoid any instability issues. A full factorial design 23 (3 factors at 2 levels) was 
utilized. The three independent variables used at two levels in this investigation were: inlet 
temperature (131°C to 196°C); aspiration rate (-21 mbar to -42 mbar); and flow rate (7.2 
ml/min to 11.4 ml/min). Four center points were added to the design space to identify any 
non-linearity in the responses. It was confirmed that all the operating conditions are 
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achievable. Minitab® 16 and Design-Expert 8 (Stat-ease®) software were utilized for the 
experimental design and analysis. To reduce systematic errors, all the experiments were 
completely randomized. 100 ml of indomethacin (1% w/v with 0.5% w/v Dowfax 2A1) 
nanosuspension (Z-average 350 nm) formulations were spray-dried at different processing 
conditions (according to design space) and dried powders were collected from the glass 
collection chamber. Multi-linear regression and ANOVA were performed to analyze the 
relationship between critical variables and responses. 	  
2.3.10. Cubic central design 
Based on the full factorial design results, response surface methodology was adopted for 
the spray drying process optimization using a cubic central design. In this study, eight 
additional experiments were added to the full factorial design to generate the response 
surface for the percent yield and particle size. Six experiments were performed at the face 
of each cube (full factorial design space) and two additional experiments were added to the 
center points. Minitab16 software was utilized for the design and analysis of the results. 
 
2.4. Results and Discussion 
2.4.1. Influence of spray drying process variables on percent yield 
As shown in Table 2.1, percent yield varied from 19.58 % w/w to 51.76 % w/w. Two main 
factors were significant: aspiration and flow rates (as shown in Table 2.2). It was noted that 
increase in aspiration rate increased the percent yield from 38% w/w to 48% w/w and 
increase in the flow rate decreased the yield of the spray-dried powder (as shown in Figure 
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2.1). Both these factors affect the percent yield by acting against one another. The 
decreased yield with increase in flow rate could be attributed to insufficient drying 
resulting in sticking of liquid or solid mass inside the drying chamber or the cyclone 
separator, or resulting in loss at the bottom of the drying chamber. By increasing the 
aspirator setting from -21 mbar to -42 mbar, yield was increased due to complete drying 
(higher outlet temperature with higher aspirator) and consequent reduction in loss of 
powder to the walls of the drying chamber. The highest yield was obtained at the lowest 
flow rate and the highest aspirator setting as shown in the contour plot (Figure 2.2). Further 
analysis using ANOVA indicated a significant effect (p < 0.05) of the critical variables on 
the response (percent yield) and no significant curvature was observed (p > 0.05). The flow 
rate had the highest impact on the percent yield followed by the aspiration rate. In addition, 
two-way interactions between critical variables (temperature*flow rate and 
temperature*aspiration) were observed to be significant. The significance of these two-way 
interactions is considered to be a result of the interdependency of the spray drying 
processing variables. For example, an increase in flow rate will result in a decrease in the 
outlet temperature. Similarly, a decrease in aspiration rate will result in a decrease in the 
outlet temperature. 
2.4.2. Influence of spray drying process variables on aggregation/particle size 
As shown in Table 2.1, the particle size of the dried powder (nano-crystals) varied from 
397 nm to 1208 nm with the larger sized particles also having larger PDIs (data not 
shown). The particle sizes of the liquid indomethacin nano-crystalline suspension 
formulations were approximately 350 nm (PDI less than 0.2) before spray drying. The 
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important spray-drying variable affecting the particle size/aggregation was the inlet 
temperature (p value less than 0.05) as shown in Table 2.3 and no other variable and/or 
interaction term was significant. It was observed that an increase in inlet temperature 
causes further aggregation as shown by particle size increase (Figure 2.3). The reason for 
the increase in particle size with higher inlet temperature could be due to generation of 
surface defects/amorphization at near or above the melting temperature of the drug 
(indomethacin melting temperature, 158°C). Since the nanoparticles experience this high 
temperature for a short time it is likely that only surface drug undergoes melting and 
amorphization resulting in particle aggregation. To confirm this phenomenon, DSC was 
performed on all the spray-dried samples and the results are shown under spray-dried 
powder characterization section. In addition, the change in particle size with temperature 
appears to be non-linear (Figure 2.3). 
2.4.3. Influence of spray drying variables on moisture content 
None of the spray drying variables had a significant effect (p value more than 0.05) on the 
moisture content of the dried samples (Figure 2.4). All the formulations had less than 3% 
w/w moisture as determined by Karl Fisher titrimetry (Table 2.1). The formulations dried 
at higher inlet temperature conditions appeared to have less moisture content compared to 
other formulations (shown in Figure 2.4). However, this was not statistically significant 
(ANOVA). A Pareto plot of the normalized effect of process variables is shown in Figure 
2.5. 
2.4.4. Influence of spray drying on the crystallinity of indomethacin 
2.4.4.1. Powder X-ray diffraction 
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Powder X-ray diffraction was performed on all the DoE independent formulations (twelve 
conditions). No differences were observed compared to control indomethacin and Dowfax 
2A1 sample mixtures as shown in Figure 2.6. All formulations contained crystalline 
indomethacin (γ polymorph), both before and after spray drying.  
2.4.4.2. Differential scanning calorimetry 
In order to determine, whether amorphization had occurred at particle surfaces, DSC 
analysis was performed on the spray dried nanosuspension formulations (as shown in 
Figure 2.7). It was observed (Figure 2.7C) that all the DoE formulations spray dried at 
higher temperature conditions (196°C) showed a glass transition temperature around 42° - 
46°C (which corresponds to the glass transition of amorphous indomethacin) as well as a 
melting temperature of 158°C (crystalline indomethacin) but other samples were 
crystalline (Figure 2.7A and 2.7B). DSC analysis for all the spray-dried formulations is 
provided in Table 4. In addition, these formulations were slightly yellow in color (Figure 
2.8), confirming the presence of amorphous indomethacin [26]. These results suggest that 
drying at higher temperatures i.e. near or above the melting temperature may pose 
problems (aggregation and crystal defects) in spray-dried formulations. 
2.4.5. Central Cubic Design to obtain the response surface for particle size and 
percent yield 
The Central Cubic Design (CCD) space and experiment results are shown in Table 2.5. As 
shown in Table 2.6A, particle size/aggregation was only dependent on the inlet 
temperature (p value less than 0.05). Log transformation was used to model the particle 
size. A few outliers were observed (probably due of aggregation of nano-crystals when 
	  
	  
	  
	  
21 
drying above the melting temperature) which resulted in non-linearity. The final equation 
for particle size with estimated coefficients of the critical variables is shown in Table 2.6B. 
The surface response for the effect of inlet temperature on particle size is shown in Figure 
2.9. A model was generated for the percent yield after spray drying of indomethacin 
nanosuspension formulations. The model is significant (p value less than 0.05) as shown in 
Table 7. The surface response for percent yield shows the dependence of percent yield on 
the aspiration and flow rates (Figure 2.10). Other interaction terms were also observed.  
 
2.5. CONCLUSIONS 
This study demonstrates the usefulness of the quality by design approach such as, DoE and 
response surface methodology to gain insight and understanding of spray drying 
processing of nanosuspensions. All the spray-dried formulations had less than 3% w/w 
moisture content. Formulations dried at higher temperatures had less moisture content 
compared to formulations dried at lower temperatures. The nanosuspension percent yield 
was mainly dependent on the flow and aspiration rates (p values <0.05). The inlet 
temperature was identified as the only critical parameter (p value <0.05) affecting particle 
aggregation during nanosuspension spray drying due to crystal melting or amorphization at 
or above melting temperature (indomethacin melting temperature 158°C). The amorphous 
content was observed in the case of formulations dried above the melting temperature. 
Particle aggregation increased with increasing temperature due to surface 
amorphization/crystal defects that lead to unstable formulations. It can be concluded that 
spray drying of nanosuspensions should be performed below the melting temperature with 
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high flow and aspiration rates for maximum recovery with minimal nano-crystal 
aggregation. 
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2.5. Tables: 
Table 2.1. Full factorial design space and responses for the process of spray drying of 
indomethacin nanosuspensions. 
 
Experimental conditions Results 
Sample 
number 
Temperature 
(°C) 
Flow Rate 
(ml/min) 
Aspiration 
(mbar) 
Outlet 
temperature 
(°C) 
Moisture 
content 
(% w/w) 
Particle 
size (nm) % Yield 
1 196 7.2 -41 127 0.545 1208 50.82 
2 164 9.3 -31 93 2 760 43.09 
3 196 11.4 -21 86 0.72 1041 46.01 
4 131 7.2 -41 80 1.5 417.8 51.76 
5 196 11.4 -41 108 0.19 1150 37.8 
6 164 9.3 -31 91 1.02 571.4 38.87 
7 196 7.2 -21 113 0.315 1118 40.3 
8 131 7.2 -21 72 1.25 397 46.39 
9 164 9.3 -31 91 1.65 644 38.12 
10 131 11.4 -41 63 1.35 492 50.88 
11 131 11.4 -21 50 1.65 430.9 19.58 
12 164 9.3 -31 92 2.1 530 39.38 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
24 
Table 2.2. Estimated effect of spray drying variables on percent yield. 
Source DF Seq SS Adj SS Adj MS F P 
Main Effects 3 348.048 348.048 116.016 23.72 0.014 
Temperature 1 4.993 4.993 4.993 1.02 0.387 
Aspiration 1 189.93 189.93 189.93 38.84 0.0008 
Flow rate 1 153.125 153.125 153.125 31.31 0.011 
2-Way Interactions 3 205.974 205.974 68.658 14.04 0.029 
Temperature* 
Aspiration 1 147.576 147.576 147.576 30.18 0.012 
Temperature*Flow rate 1 51.918 51.918 51.918 10.62 0.047 
Aspiration*Flow rate 1 6.48 6.48 6.48 1.33 0.333 
3-way Interactions 1 249.314 249.314 249.314 50.98 0.006 
Temperature*Aspiration
*Flow rate 1 249.314 249.314 249.314 50.98 0.0006 
Curvature 1 25.256 25.256 25.256 5.16 0.108 
Residual Error 3 14.671 14.671 14.671 4.89   
Pure Error 3 14.671 14.671 14.671 4.89   
Total 11 843.263         
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Table 2.3. Estimated effect of spray drying variables on particle size. 
Source DF Seq SS Adj SS Adj MS F P 
Main Effect 3 975517 975517 325172 32.01 0.009 
Temperature 1 965564 965564 965564 95.05 0.002 
Flow rate 1 90 90 90 0.01 0.931 
Aspiration 1 9863 9863 9863 0.97 0.397 
2-way Interactions 3 9541 9541 3180 0.31 0.456 
Temperature*Flow rate 1 7387 7387 7387 0.73 0.456 
Temperature*Aspiration 1 1714 1714 1714 0.17 0.709 
Flow rate* Aspiration 1 440 440 440 0.04 0.849 
3-way Interactions 1 57 57 57 0.01 0.945 
Temperature*Flow rate* 
Aspiration 1 57 57 57 0.01 0.945 
Curvature 1 64470 64470 64470 6.35 0.086 
Residual Error 3 30477 30477 10159 
 
  
Pure Error 3 30477 30477 10159 
 
  
Total 11 1080062         
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Table 2.4. DSC results showing melting, glass transition, and crystallization temperatures of all 
DoE formulations. 
Sample 
number 
Processing inlet 
temperature (°C) 
Melting temp 
°C (Tm) 
Glass transition 
temp °C (Tg)  
Melting 
enthalpy (J/g) 
1 196 158.32 46.99 64.7 
2 164 156.52 n/a 65.1 
3 196 156.76 48.14 64.05 
4 131 156.1 n/a 65.27 
5 196 157.15 46.21 65 
6 164 156.78 n/a 66.14 
7 196 158.05 46.63 62.56 
8 131 156.79 n/a 60.16 
9 164 159.17 n/a 67 
10 131 155.84 n/a 64.7 
11 131 156.23 n/a 64.03 
12 164 155.39 n/a 65.25 
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Table 2.5. Cubic center design with yield and particle size of spray dried indomethacin 
nanosuspension formulations. 
 
Experimental conditions Results 
Sample 
number 
Temperature 
(°C) 
Aspiration 
(mbar) 
Flow rate 
(ml/min) % Yield 
Particle size 
(nm) 
1 164 -31 9.3 43.09 573.8 
2 196 -21 11.4 46.01 1041 
3 131 -41 7.2 51.76 417.8 
4 196 -41 11.4 37.8 1150 
5 131 -21 7.2 46.39 397 
6 164 -31 9.3 38.87 530 
7 131 -21 11.4 19.58 430.9 
8 196 -41 7.2 50.82 1208 
9 164 -31 9.3 38.12 571.4 
10 131 -41 11.4 50.88 492 
11 196 -21 7.2 40.3 1118 
12 164 -31 9.3 39.38 791 
13 164 -41 9.3 42.17 829.1 
14 196 -31 9.3 34.47 1564 
15 164 -31 9.3 41.97 760 
16 164 -21 9.3 39.79 669.4 
17 164 -31 11.4 46.06 548.4 
18 164 -31 7.2 46.42 1012 
19 131 -31 9.3 38.77 571.2 
20 164 -31 9.3 47.7 644 
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Table 2.6. Estimated effects (A) and coefficients (B) of spray drying critical variables on particle 
aggregation. 
  Sum of   Mean F p-value   
Source Squares df Square Value Prob > F   
Model 2.46 3 0.82 23.23 < 0.0001 significant 
  A-Inlet temperature 2.39 1 2.39 67.71 < 0.0001   
  B-Aspirator 0.04 1 0.04 1.13 0.3033   
  C-Flow rate 0.03 1 0.03 0.84 0.3724   
Residual 0.57 16 0.035 
  
  
Lack of Fit 0.43 11 0.039 1.45 0.357 not significant 
Pure Error 0.13 5 0.027 
  
  
Cor Total 3.03 19         
	  
	  
Ln(Particle size)  = 
  4.97392 
   0.16311 * Inlet temperature 
0.012651  * Aspirator 
 -0.054572  * Flow rate 
 
     
 
 
 
 
 
	  
	  
	  
	  
29 
Table 2.7. Estimated effect (A) and coefficients (B) of spray drying critical variables on percent 
yield.	   
  Sum of   Mean F p-value   
Source Squares df Square Value Prob > F   
Model 744.91 5 148.98 8.73 0.0006 significant 
  B-Aspirator 171.06 1 171.06 10.02 0.0069   
  C-Flow rate 125.03 1 125.03 7.32 0.017   
  AB 147.58 1 147.58 8.64 0.0108   
  AC 51.92 1 51.92 3.04 0.1031   
  ABC 249.31 1 249.31 14.6 0.0019   
Residual 238.99 14 17.07 
  
  
Lack of Fit 174.97 9 19.44 1.52 0.3363 not significant 
Pure Error 64.02 5 12.8 
  
  
Cor Total 983.9 19 
   
  
	  
	  
% Yield  = 
    40.16556 
     3.70086 * Aspirator 
   -11.95022  * Flow rate 
   -0.24549  * Inlet temperature * Aspirator 
 0.98102  * Inlet temperature * Flow rate 
 -0.01396  * Inlet temperature * Aspirator * Flow rate 
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2.6. Figures: 
	  
	  
	  
 
Figure 2.1. Plot showing the mean effect of aspiration and flow rates on percent yield. 
 
 
Figure 2.2. Contour plot showing the effect of aspiration (y-axis) and flow rates (x-axis) on the 
percent yield.  
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Figure 2.3. Plot showing the effect of inlet temperatures on nanoparticle size.  
 
 
Figure 2.4. Plot showing the effect of inlet temperature on the moisture content of spray dried 
powders. 
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Figure 2.5. Pareto plot showing the standardized effect of spray drying processing variables on 
moisture content. 
 
 
Figure 2.6. PXRD of all DoE formulations (twelve samples). Refer to Table 1 for experimental 
conditions 1 through 12. 
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Figure 2.7A. DSC plot showing all formulations spray dried at the lowest inlet temperature 
condition (131°C). 
 
 
Figure 2.7B. DSC plot showing all formulations spray dried at the center point temperature 
condition (164°C). 
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Figure 2.7C. DSC plot showing all formulations spray dried at the highest temperature condition 
(196°C). 
 
 
Figure 2.8. Photograph showing spray-dried formulations (Note: Samples 1, 3, 5 and 7 are 
relatively yellow in color compared to the other samples). 
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Figure 2.9. Response surface to predict particle size after spray drying of indomethacin 
nanosuspensions. 
 
	  
	  
Figure 2.10. Response surface to predict percent yield after spray drying of indomethacin 
nanosuspensions. 
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Chapter 3 
	  
	  
	  
	  
Formulation Parameters of Crystalline Nanosuspensions on Spray Drying 
Processing: A DoE Approach 
	  
	  
Abstract 
Nano-crystalline suspensions offer a promising approach to improve dissolution of BCS 
class II/IV compounds. Spray drying was utilized as a downstream process to improve the 
physical and chemical stability of dried nano-crystals. The effect of nano-crystalline 
suspension formulation variables on spray-drying processing was investigated. Naproxen 
and indomethacin nano-crystalline formulations were formulated with either Dowfax 2A1 
(small molecule) or HPMC E15 (high molecular weight polymer) and spray drying was 
performed. A DoE approach was utilized to understand the effect of critical formulation 
variables i.e. type of stabilizer, type of drug, ratio of drug-to-stabilizer and drug 
concentration. The powders were analyzed for particle size, moisture content, powder X-
ray diffraction and dissolution. A dialysis sac adapter for USP apparatus II was developed 
which provided good discrimination between aggregated and non-aggregated formulations. 
Nano-crystal aggregation was dependent on the drug-to-stabilizer ratio. The glass 
transition temperature and the charge effect played a dominant role on spray-dried powder 
yield. Those formulations with low drug-to-excipient ratios were less aggregating and 
showed faster dissolution compared to those formulations with high drug-to-excipient 
ratios. All stable (less aggregated) formulations were subjected to accelerated storage 
stability testing. The Flory-Huggins interaction parameter (between drug and excipients) 
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correlated with the spray-dried nano-crystal formulations stability. 
 
3.1. Introduction 
	  
The popularity of nanosuspensions has increased over the past decade due to the escalation 
(approximately 40%) in the number of poorly soluble drug candidates coming out of drug 
discovery [1-5]. The aqueous solubility of these drug molecules is in the order of a few 
nanograms to hundreds of nanograms per milliliter. These poorly soluble drug candidates 
must be formulated appropriately to enhance their dissolution rate and/or solubility and 
subsequently oral bioavailability. Apart from poor oral bioavailability, these drugs have 
several other disadvantages such as, fed versus fasted variation in bioavailability and the 
requirement of high doses to achieve therapeutic responses [6]. Several approaches have 
been utilized to formulate poorly soluble compounds such as solid dispersions, salt 
formation, prodrugs, screening for more soluble crystalline forms and preparation of 
nanosuspensions. The high exposed surface area of the nano-crystals increases the 
dissolution rate and hence oral bioavailability [6-8]. Apart from a bioavailability 
advantage, nano-suspension formulations have been shown to increase the chemical 
stability in some cases. For example, a paclitaxel aqueous nano-suspension formulation 
was stable up to 4 years (when stored at 4°C) [9] compared to un-milled paclitaxel (80% 
degradation within 25 minutes) in water [10]. The reason of nano-suspension stabilization 
was due to shielding or protection of the nano-sized crystalline paclitaxel by surface 
stabilizers.  
There are several commercially available nano-particulate formulations and others are 
currently being evaluated in clinical trials [11]. Nanosuspensions can be defined as 
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suspensions of nano-sized drug particles suspended in stabilizer/s solutions. These 
solutions can be aqueous or non-aqueous and the typical size range for pharmaceutical 
nanosuspensions is 100 to 1000 nm. Nanosuspensions fall under the category of colloidal 
dispersions and can be prepared either via “top-down” or “bottom-up” approaches. Top-
down approaches are based on milling or grinding of the drug particles in aqueous or 
mixtures of aqueous and non-aqueous solvents to achieve the required particle size. 
Bottom-up approaches are based on precipitation of the drug from solution (drug dissolved 
in organic solvent) using a solvent such as distilled water where the drug is insoluble. The 
size and stability of the nano-suspension is dependent on the HLB of stabilizer and 
solubility of drug in stabilizer solutions, in bottom-up and top-down approaches 
respectively [12]. In addition, particles generated using these approaches may yield 
amorphous or partially crystalline material and their physical stability can be a critical 
issue [13].  
Crystalline nanosuspensions have high surface area to volume ratios and thus (according to 
the Noyes-Whitney equation, Equation 3.1) [14] have faster dissolution rates and increased 
oral bioavailability.  
           Equation 3.1 
Where dC/dt is change in concentration, D is the diffusion coefficient, S is the surface area 
of the drug particle, h is the thickness of the diffusion layer, Cs is the saturation solubility 
of the drug particle, C is the concentration of the drug in solution, and V as the total 
volume of the solution. 
!"!" = !"!ℎ (!! − !) 
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In addition, according to the Kelvin equation (Equation 3.2), saturation solubility (in terms 
of vapor pressure) of the drug is dependent on the drug particle size (which translates to 
curvature effects) [15]. Theoretically, reduction in particle size will cause an increase in 
drug solubility. However, the predicted increase in saturation solubility for pharmaceutical 
nanosuspensions (approximately 300 nm) is marginal compared to un-milled particles. 
                     Equation 3.2 
Where S=solubility, S0=solubility of bulk material, R=gas constant, V=molar volume, 
T=temperature, d=diameter of particle and γ= surface free energy. 
Nanosuspensions being a liquid dosage form are physically and chemically unstable. Drug 
particles in aqueous environment can undergo chemical degradation such as hydrolysis. 
Nano-suspension formulations are known to undergo Ostwald’s ripening as well as phase 
separation or precipitation. To prevent chemical as well as physical instability, drying of 
nanosuspensions is employed. Freeze and spray-drying processes are typically used to dry 
nanosuspensions [16, 17]. The advantages of dried formulations are improvement in 
chemical and physical stability and processibility into tablets or capsules. The drying 
process itself can lead to issues such as, aggregation on re-dispersion of dried powders, 
drug degradation, delayed and dissolution rates. There are several reports which deal with 
spray and/or freeze-drying of nanosuspensions [16-21] but none of these explain the 
importance of the process and formulations parameters during nano-suspension drying. 
Our previous research has focused on the effect of spray drying process parameters on the 
critical quality attributes (CQA) of nanosuspensions. This current study highlights the 
!!! = exp!(4ϒ!!"#) 
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importance of critical nano-suspension formulation variables involved during spray drying 
processing. 
We have utilized a Design of Experiment  (DoE) approach to classify and quantify all the 
critical formulation variables involved during spray drying of nanosuspensions. We have 
chosen two poorly soluble biopharmaceutical classification system (BCS) class II model 
drugs (i.e. indomethacin and naproxen).  Dowfax 2A1 (small molecule ionic surfactant) 
and HPMC E15 (non-ionic polymer) were used for the stabilization of liquid nano-
suspension formulations. Based on our preliminary study, we have selected four critical 
parameters i.e. type of drug, type of excipient, concentration of drug and ratio of drug-to-
stabilizer for this study.  A full factorial design was utilized with two qualitative and two 
quantitative factors. The CQAs were particle size, yield, moisture content, polymorphic 
form, dissolution and stability of the spray-dried nano-crystal powders. ANOVA was 
utilized to analyze the effect of critical formulation parameters on the quality attributes of 
spray-dried powders. To the best of our knowledge, no exhaustive DoE study has been 
conducted that describes the effect of nano-suspension formulation variables on the quality 
of the spray-dried powder. 
At present, United States Pharmacopeia (USP) does not have any official or standard 
method(s) for in vitro release testing of colloidal/disperse dosage forms. Currently used 
techniques can be broadly divided into two categories: 1) sample and separation methods; 
and 2) membrane diffusion methods (such as dialysis sac, reverse dialysis sac, micro-
dialysis, and Franz cells). These techniques are required to isolate the dosage form from 
the release media for analytical purposes. However, these existing methods do not use 
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official USP dissolution/release apparatus. Accordingly, the methodology changes with 
operator and laboratory, introducing undesirable variations. Therefore, results from 
different sources are usually not comparable. The present study aims to address this 
problem by designing and developing a dialysis adapter to be used in conjunction with 
compendial USP dissolution apparatus II. 
 
3.2. Materials 
Indomethacin USP, γ polymorph, was purchased from PCCA (Houston, TX). Naproxen 
was purchased from Gallipot. Dowfax 2A1 (alkyldiphenyloxide disulfonate) and HPMC 
E15 (premium LV) were generously gifted by Dow Chemical Company (Midland, MI). 
HPLC grade acetonitrile (ACROS chemicals) was purchased from Fisher scientific 
(Waltham, MA). Hermetic pans and lids were purchased from TA instruments (New 
Castle, DE) and Float-A-Lyzer dialysis sacs (MWCO 1000 kDa) were purchased from 
Spectrum labs (Spectrum Laboratories Inc., California). 
 
3.3. Methods 
3.3.1. Preparation of crystalline nanosuspensions 
All the nano-suspension formulations were prepared using a wet media milling (top-down) 
approach. Briefly, the stabilizer was dissolved in distilled water and the drug was 
suspended in the stabilizer solution using a magnetic stirrer. The macro-suspensions were 
stirred to ensure complete wetting of the drug by the stabilizer. The stirred macro-
suspension formulations (120 mL) were processed via a Netzsch® media mill. All nano-
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suspension formulations were milled for 2 - 3 hours under controlled temperature 
conditions i.e. below 25°C. The particle size of all nano-suspension formulations was 
approximately 250 nm with a PDI (polydispersity index) of less than 0.2 (i.e. 
monodisperse systems). 
3.3.2. Spray drying of crystalline nanosuspensions 
Indomethacin and naproxen nano-suspension formulations were spray dried using a lab 
scale Buchi spray dryer B-290 (Buchi labortechnik AG, Flawil, Switzerland). Briefly, the 
spray dryer was pre-conditioned using distilled water. Once equilibrated, the required 
amount (either 20 ml for 5% w/v or 100 ml for 1% w/v nano-suspension formulations) of 
the nano-suspension formulation was spray dried at a pre-optimized condition (i.e. feed 
rate 5 mL/min, inlet temperature 150°C and aspirator setting -31 mbar). Atomizing air was 
maintained constant at 40 mm Hg (air flow approximately 600 L/hour) and a 0.5 mm spray 
nozzle was used. The dried samples were collected and evaluated for yield, particle size 
and drug polymorphic form. 
3.3.3. Powder X-ray diffraction (PXRD) 
PXRD (powder X-ray diffraction) was used to study the crystallinity of the dried samples. 
Diffraction patterns were obtained using an X-ray diffractometer (Bruker AXS Model D2 
Phase diffractometer, Germany) using Cu-kα radiation (30 kV voltage and 10 mA current). 
All the scans were performed at 1°/min from 5° to 40° 2θ angle aided by goniometer. 
3.3.4. Differential scanning calorimetry 
Modulated temperature DSC (mtDSC) was performed using a TA Q1000 calorimeter (TA 
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instrument, New Castle, DE). The instrument was calibrated for enthalpy and heat capacity 
using indium and sapphire, respectively. About 5 - 10 mg of samples were hermetically 
sealed and analyzed. Nitrogen was used as a purging gas; at a flow rate of 50 mL/min. 
Samples were heated at 2°C/min at amplitude of +/- 0.82°C with a period of 80 seconds. 
Data were analyzed using TA universal analysis software.  
3.3.5. Percent yield 
For calculation of percent yield, the drug amounts in the liquid and dried nano-suspension 
formulations were determined using an HPLC-UV method (as described below). Briefly, 
the nano-suspension formulations were dissolved in the mobile phase and this solution was 
used to quantify the drug amount. The formula used for calculation of the % yield was: 
          Equation 3.3 
Note: Drug mass in and out represents, the total amount of drug (in nanosuspensions) that 
was spray dried and that was recovered (dried powder), respectively. 
3.3.6. HPLC-UV method 
The standard curves of indomethacin and naproxen were generated using a Perkin-Elmer 
(Waltham, MA) HPLC system (200 series) connected to a UV system. 
3.3.6.1. Indomethacin HPLC-UV method 
The amount of indomethacin was quantified using C-18 Zorbax® column (4.6 mm×150 
mm, 5µm) and the mobile phase was a mixture of two phases (A/B) at 50:50 v/v ratio. 
Phase A was a mixture of water and phosphoric acid (0.2% v/v) and phase B was HPLC 
% Yield = Drug Mass Out ×
100
Drug Mass In
%!
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grade acetonitrile. The flow rate was maintained constant at 1.3 ml/min and the UV 
absorbance was measured at 237 nm. The temperature of the column was maintained at 
30°C. Various dilutions were made in the mobile phase to prepare a standard curve. The 
chromatographs were analyzed using a PeakSimpleTM Chromatography System. The 
concentration range for linearity was 0.005 mg/ml to 0.2 mg/ml with an R2 value 0.99.  
3.3.6.2. Naproxen HPLC-UV method 
Naproxen amount was quantified using C-18 Zorbax® column (4.6 mm×150 mm, 5µm) 
and the mobile phase was a mixture of two phases (A/B) at 50:50 v/v ratio. Phase A was a 
mixture of water and acetate buffer (20 mM) and phase B was HPLC grade acetonitrile. 
The pH of the mixture was adjusted to pH 4.4 using acetic acid. The flow rate was kept 
constant at 1.0 ml/min and the UV absorbance was measured at 270 nm. The temperature 
of the column was maintained at 30°C. Various dilutions of the mobile phase were made to 
prepare a standard curve. The chromatographs were analyzed using a PeakSimpleTM 
Chromatography System. The concentration range for linearity was 0.001 mg/ml to 0.1 
mg/ml with an R2 value 0.9978. 
3.3.7. Particle size measurement 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments, Worcestershire, UK) to determine the Z-average and PDI of the 
nanosuspensions before and after spray drying processing. Briefly, the spray-dried 
powders were suspended in saturated and filtered (0.2 µm membrane filter) solution of the 
drug (either indomethacin or naproxen) in 30% glycerin solution to avoid any discrepancy 
from dissolution of nano-particles during the measurement. The viscosity of the dispersant 
solution (measured using a Brookfield viscometer model DV-III, Middleboro, MA) was 
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used to calculate the particle size of the formulations. Each measurement was performed in 
triplicate and the mean values were reported. 
3.3.8. Dissolution experiment 
Dissolution experiments were conducted using a Sotax® USP apparatus II. Float-A-Lyzer 
dialysis sacs were secured to the Sotax USP apparatus II using an in-house developed 
adapter (the Float-A-Lyzer cap was glued to a plastic rod which was then fixed to the cover 
of the Sotax USP II apparatus). The immersion depth of the dialysis sac was controlled by 
the length of the adapter (l) and was carefully adjusted so that the dialysis portion was fully 
immersed while the cap was always above the dissolution media (as shown in Figures 3.1, 
3.2 and 3.3). The spray-dried formulations were re-suspended in 1 mL of distilled water 
and placed into the dialysis sacs (cutoff 1000 KDa). The dialysis sacs were screwed to the 
fixed cap (as shown in Figure 3.1 and 3.3) and the dissolution experiments were 
performed. All the dissolution experiments were conducted at 37°C in 900 ml (sink 
condition) of phosphate buffer (50 mM, pH 6.8) with 50 rpm paddle speed. At each time 
point, 1 ml of sample was withdrawn from the dissolution chamber (outside the dialysis 
sac) and replaced with fresh phosphate buffer. All the samples were analyzed using the 
HPLC method as described. 
3.3.9. Stability study 
All spray-dried formulations were stored at 40°C and 75% relative humidity (RH) for three 
months in closed vials. After three months, the samples were analyzed for particle size and 
polymorphic changes, if any. 
3.3.10. Design of Experiment (DoE) 
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Based on our preliminary experiments, drug type, concentration of nanosuspension, type of 
stabilizer and drug to stabilizer ratio were identified as important formulation variables that 
may significantly affect the particle aggregation and yield during spray drying processing. 
To understand the effects of the formulation variables a design of experiment (DoE) 
approach was adopted and a full factorial design was utilized. For this study, two model 
APIs (i.e. naproxen and indomethacin) and stabilizers i.e. Dowfax 2A1 (small molecule) 
and HPMC E15 (large molecular weight) were tested. The experimental design space 
consisted of 24 experiments (4 factors at 2 levels). All four independent variables at two 
levels were: type of drug (naproxen and indomethacin); concentration of drug 
nanosuspensions for spray drying (1% w/v to 5% w/v); type of excipient (Dowfax 2A1 and 
HPMC E15) and drug to stabilizer ratio in nanosuspensions (10 parts to 1 part and 10 parts 
to 5 parts). It was confirmed that all the levels of the design space can be achieved and 
further can be applied to other drug formulations. 20 ml, in case of 5% w/v and 100 ml, in 
case of 1% w/v nanosuspensions (equal amount of drug in each case) were spray-dried at 
an optimized condition. The dried powder was collected from the collection chamber for 
further analysis. Minitab® 16 (Minitab Inc. State college, PA) and Design expert 8 (Stat-
ease Inc., Minneapolis, MN) were utilized to design and analysis DoE results. To reduce 
any effect of systematic errors all the experiments were randomized. 
 
3.4. RESULTS AND DISCUSSIONS 
3.4.1. Effect of formulation variables on nano-crystal aggregation during spray 
drying 
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As shown in Table 3.1, all spray-dried formulations showed aggregation. One critical 
variable was identified as a significant parameter for nano-crystals aggregation i.e. drug-to-
stabilizer ratio. All other variables were not significant as shown in Table 3.2. It was noted 
that formulations containing high concentrations of stabilizers (i.e. either Dowfax 2A1 or 
HPMC E15) were less aggregated compared to formulations with lower stabilizer 
concentrations (Figure 3.4). Both small molecule (Dowfax 2A1) and large molecular 
weight stabilizers (HPMC E15) had similar effects on aggregation after spray drying 
processing. HPMC E15 containing formulations appeared slightly better (i.e. less 
aggregated) than Dowfax 2A1 containing formulations but differences were statistically 
insignificant. Nano-crystal aggregation was independent of the drug concentration and the 
drug itself (i.e. naproxen and indomethacin showed similar aggregation). Average particle 
sizes (z-average) of all the formulations are given in Table 3.1. A plot of the interactions 
between formulation variables is shown in Figure 3.5. 
3.4.2. Effect of formulation variables on powder yield during spray drying  
As shown in Table 1, percent yield during spray drying varied from 25% (sample 14) to 
72% (sample 7). It was interesting to observe that all the formulation variables were 
critical to the nanosuspension yield following spray drying (as shown in Table 3.3). 
Naproxen containing formulations had lower yield compared to indomethacin 
formulations. This may be due to the lower melting temperature of naproxen compared to 
indomethacin (Table 3.4), which resulted in increased adhesion to the glass chambers 
walls. Both formulations were spray dried at an inlet temperature of 150°C. Naproxen 
containing formulations have a lower melting temperature i.e. 152°C (close to the inlet 
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temperature) and thus may form amorphous regions at the particle surfaces causing 
sticking to the chamber walls and lower yields. Drug concentration in the nanosuspension 
formulations (1% w/v and 5% w/v) also affected the yield during spray drying. Each spray 
drying experiment was performed with a constant amount of drug i.e. 20 ml of 5% w/v or 
100 ml of 1% w/v nanosuspension. The reason for lower yields of the 1% w/v formulations 
may be due to the higher probability of drug particle adherence to the chambers since this 
formulation has a five times larger volume (i.e. 100 ml versus 20 ml) and therefore has to 
be spray dried for a five times longer period of time. The nanocrystal yield also showed a 
dependency on the type of excipient (i.e. Dowfax 2A1 and HPMC E15). All Dowfax-2A1 
containing formulations had superior yields compared to the HPMC E15 containing 
formulations (as shown Figures 3.6 and 3.7). This maybe due to the charge effect, as 
Dowfax 2A1 is a negatively charged surfactant compared to HPMC E15 (non-ionic 
stabilizer). The Buchi spray dryer is coated with a special anti-static coating to repel 
charges (i.e. charged powder) away from the glass surface and thus improve the recovery. 
The nanosuspension formulations containing Dowfax-2A1 were highly negatively charged 
(high negative zeta potential) compared to the HPMC E15 containing formulations (as 
shown in Table 3.5). This charge effect of Dowfax-2A1 formulations could be the reason 
for the higher yields obtained with these formulations. The effect of drug-to-excipient ratio 
on the percent yield is complex. It was observed that by decreasing the drug-to-excipient 
ratio from 10:1 to 2:1 resulted in an increase in the yield during spray drying (Figure 3.7). 
In the case of Dowfax-2A1 containing formulations, an increase in Dowfax-2A1 
concentration increases the negative charge and thus maybe responsible for the higher 
yields (as shown in Table 3.5A). In the case of HPMC E15 (non-ionic) containing 
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formulations, it is speculated that an increase in the HPMC E15 concentration will increase 
the Tg of the dried powder (greater number of HPMC E15 molecules per spray droplet) 
and this will causes less sticking inside the chamber. Higher glass transition temperature 
(Tg) formulations generally have higher yields compared to lower Tg formulations (data 
not shown).  
3.4.3. Characterization of spray-dried powder: 
3.4.3.1 Powder X-ray diffraction 
As shown in powder x-ray diffraction, no changes were observed in any of the 
formulations (Figure 3.8 and 3.9). All the formulations were crystalline in nature.  
3.4.3.2. Moisture content 
All the formulations had less than 3% w/w moisture content (data not shown).  
3.4.4. Dissolution performance of spray-dried product 
The dissolution experiment was conducted using a newly developed dialysis sac adapter 
for the USP apparatus II, as described in the methods section. All dissolution experiments 
were performed in phosphate buffer (50 mM) at pH 6.8. Approximately 20 mg of drug as 
re-suspended formulations was added to the dialysis sacs and the dissolution experiments 
were performed in triplicate. As shown in Figures 3.10 and 3.11, aggregated formulations 
resulted in slower drug release or dissolution compared to less aggregated formulations. 
All highly aggregated formulations had lower drug-to-stabilizer ratios (as shown in Table 
3.1). The initial (0-60 minutes) drug release rates of these formulations were similar this is 
probably due to non-aggregated nanoparticulates in these formulations. Diffusion of 
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naproxen and indomethacin in solution are shown for comparison (Figures 3.12 and 3.13).  
3.4.5. Stability studies: 
3.4.5.1. Particle size 
All less aggregated formulations (i.e. 2:1 drug-to-excipient ratio containing formulations) 
were stored at 40°C at 75% RH for three months and particle analysis was performed. It 
was observed that for the naproxen-HPMC E15 formulations (samples #15 and #16), the 
spray-dried nanocrystal powders were stable (i.e. less aggregation) after spray drying as 
well as during accelerated storage conditions compared to indomethacin-HPMC E15 
formulations (sample #7 and #8), as shown in Table 3.6. This is considered due to the 
favorable interactions between HPMC E15 and naproxen. In the case of Dowfax-2A1 
containing formulations, both naproxen-Dowfax 2A1 (samples #11 and #12) and 
indomethacin-Dowfax 2A1 (samples #3 and #4) spray-dried nanocrystal powders showed 
aggregation after spray drying as well as during storage conditions.  
To further understand the mechanism of nanocrystal aggregation following spray drying 
and during storage stability, the Flory-Huggins interaction parameter (χ chi) was calculated 
from the melting point depression approach [22, 23]. This approach is used by scientists to 
calculate the interaction parameters between different APIs and polymer systems in order 
to predict the stability of solid dispersions [24, 25]. However, this method has not been 
applied or correlated to the stability of crystalline nanosuspension systems. The limitation 
of this approach (i.e. melting point depression to calculate interaction value), is that it can 
only be applied to systems where melting point depression is observed [22, 23, 24]. 
Physical mixtures of naproxen and indomethacin with HPMC E15 or Dowfax-2A1 were 
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prepared at different concentrations. Modulated DSC of all the physical mixtures was 
performed to check for depression in the drug melting point. As shown in Figure 3.13, the 
melting point of naproxen-HPMC E15 was greatly depressed compared to indomethacin-
HPMC E15 suggesting a stronger and more favorable interaction between naproxen and 
HPMC E15. As shown in Figure 3.12, Dowfax-2A1 does not significantly affect the 
melting point of the indomethacin or naproxen, suggesting no or weak interaction. Dowfax 
2A1 is a negatively charged small molecule surfactant and therefore unlikely to affect the 
Flory-Huggins interaction parameter, compared to HPMC E15 (un-charged polymer). The 
negative charge on Dowfax 2A1 is likely contributing to the nano-crystal powder stability. 
Dowfax 2A1-naproxen or Dowfax 2A1-indomethacin nanosuspension formulation data 
cannot be described by the interaction parameter determined via the melting depression 
approach. As little or no melting point depression was observed with Dowfax 2A1 via 
modulated DSC (Figure 3.12 A and B), no further chi or interaction value calculations 
were performed for indomethacin or naproxen with Dowfax 2A1. The interaction 
parameter (χ) value was calculated for both naproxen and indomethacin with HPMC-E15. 
The relationship of melting point depression and the interaction parameter is shown below:  
 Equation 3.4 
Where 𝑇!!"# is the melting temperature of the drug in the presence of the polymer, 𝑇!!"#$is 
the melting temperature of the drug in the absence of the polymer,  is the heat of 
fusion of the pure drug, 𝛷!"#$%&' is the volume fraction of the polymer, 𝛷!"#$ is the 
volume fraction of the drug and m is the ratio of the molecular volume of the polymer to 
1!!!"# − 1!!!"#$ = − !!"!"# !"!!"#$ + 1− 1! !!"#$%&' + !"!"#$%&'!  
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that of the lattice site (or volume of the drug). A plot of !!!!"# − !!!!"#$ ∗ (𝛥𝐻!"#/-R)-𝑙𝑛𝛷!"#$ − 1− !! 𝛷!"#$%&'   versus 𝜒𝛷!"#$%&'! will yield a linear relationship with a 
slope equal to χ. A negative, zero or positive value of χ will represent favorable, ideal and 
no interaction between systems, respectively. The physical properties used in the 
calculation of χ are shown in Table 3.7. The calculated χ values (slope values) of 
indomethacin-HPMC E15 and naproxen-HPMC E15 were -0.3 and -3.4, respectively 
(Figure 3.14). A -3.4 value corresponds to strong interaction between naproxen and HPMC 
E15, which might be the reason for less nanocystal aggregation compared with the 
indomethacin-HPMC E15 formulations (interaction parameter value -0.3). 
3.4.5.2. Polymorphic form 
Powder XRD (Figure 3.15) was performed for all the formulations after 3 months of 
storage stability. No polymorphic changes were observed during storage conditions.  
 
3.5. CONCLUSIONS 
This is the first report, which deals with the effect of formulation variables on the critical 
quality attributes of spray-dried nano-crystal powder. The aggregation tendency of spray-
dried nano-crystal powders showed a dependency on the drug-to-stabilizer ratio. The 
formulations containing higher concentrations of excipients showed less aggregation 
compared to formulations containing lower concentrations of excipients. We have 
developed a dialysis sac adapter for USP apparatus II. This adapter can be utilized with any 
USP dissolution apparatus II with minor modifications. A dissolution method utilizing 
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dialysis sacs with USP apparatus II was able to distinguish aggregated versus non-
aggregated nano-sized formulations. This dialysis sac adapter can also be utilized for other 
liquid formulations such as, liposome, microsphere etc. This method can be utilized for the 
routine quality control assays performed in the pharma industry and potentially for the 
development IVIVC. The nano-crystal yield during spray drying showed dependency on 
all factors studied i.e. drug, excipient, drug to stabilizer ratio and concentration of the drug. 
The Tg and charge of the formulation played a dominant role during the spray drying 
process. It is observed that formulations with higher concentrations of HPMC E15 resulted 
in higher yields compared to formulations with lower concentrations of HPMC E15. This 
may be due to a difference in Tg (as higher Tg is expected with formulations containing 
higher HPMC-E15 concentration which will result in less sticking to the drying chamber 
and higher yields). On the other hand, using a charged excipient (such as negatively 
charged surfactants) for nano-crystal stabilization and spray drying improved the yield. In 
addition, we have applied chi (χ) interaction parameter to the stability of polymer-
stabilized nano-sized systems (i.e. nano-crystalline formulations). The stability of the 
spray-dried powder correlated with the interaction parameter (calculated using the melting 
point depression approach) between the drugs (i.e. naproxen and indomethacin) and 
HPMC E15 (high molecular weight polymer). The melting point depression approach may 
also be utilized to select the best excipient/s for other BCS class II/IV APIs nano-
crystalline formulations. However, different drugs and stabilizers must be tested to validate 
the application of this approach to nano-crystal stabilization.  
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3.6. Tables: 
Table 3.1. Full factorial design of formulation variables involved during spray drying processing of 
crystalline nanosuspensions. 
No. Drug Excipient 
Ratio of 
drug-to-
excipient 
Conc. of 
the Drug 
(w/w) 
Particle 
Size (% 
Increase) 
Percent 
Yield 
(%) 
1 Indomethacin Dowfax 2A1 10 to 1 5 1021.41 52.54 
2 Indomethacin Dowfax 2A1 10 to 1 1 857.91 48.76 
3 Indomethacin Dowfax 2A1 2 to 1 5 171.25 66.38 
4 Indomethacin Dowfax 2A1 2 to 1 1 160.68 53.77 
5 Indomethacin HPMC E15 10 to 1 5 597.55 47.14 
6 Indomethacin HPMC E15 10 to 1 1 612.19 27.40 
7 Indomethacin HPMC E15 2 to 1 5 198.00 72.05 
8 Indomethacin HPMC E15 2 to 1 1 187.84 53.41 
9 Naproxen Dowfax 2A1 10 to 1 5 925.70 61.13 
10 Naproxen Dowfax 2A1 10 to 1 1 777.97 53.36 
11 Naproxen Dowfax 2A1 2 to 1 5 215.65 60.85 
12 Naproxen Dowfax 2A1 2 to 1 1 214.78 54.59 
13 Naproxen HPMC E15 10 to 1 5 1071.34 41.09 
14 Naproxen HPMC E15 10 to 1 1 774.25 25.27 
15 Naproxen HPMC E15 2 to 1 5 129.67 52.25 
16 Naproxen HPMC E15 2 to 1 1 116.27 42.14 
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Table 3.2. Estimated effect of nanosuspension formulation variables on particle size. 
Source DF Seq SS Adj SS Adj MS F P 
Drug 1 10962 10962 10962 0.62 0.47 
Excipient 1 27081 27081 27081 1.54 0.27 
Ratio of drug to excipient 1 1718833 1718833 1718833 97.50 0.00 
Concentration of drug 1 24702 24702 24702 1.40 0.29 
Drug*Excipient 1 20527 20527 20527 1.16 0.33 
Drug*Ratio of drug to excipient 1 15727 15727 15727 0.89 0.39 
Drug*Conc. of drug 1 5238 5238 5238 0.30 0.61 
Excipient*Ratio of drug to excipient 1 9855 9855 9855 0.56 0.49 
Excipient*Conc. of drug 1 17 17 17 0.00 0.98 
Ratio of drug to excipient*Conc. of drug 1 19509 19509 19509 1.11 0.34 
Error 5 88142 88142 17628 
 
  
Total 15 1940590         
S = 132.772; R-Sq = 95.46% ; R-Sq(adj) = 86.37% 
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Table 3.3. Estimated effect of nanosuspension formulation variables on percent yield during spray 
drying. 
Source DF Seq SS Adj SS 
Adj 
MS F P 
Drug 1 59.06 59.06 59.06 8.10 0.04 
Excipient 1 513.43 513.43 513.43 70.45 0.00 
Ratio of drug to excipient 1 609.67 609.67 609.67 83.66 0.00 
Concentration of drug 1 560.78 560.78 560.78 76.95 0.00 
Drug*Excipient 1 142.27 142.27 142.27 19.52 0.01 
Drug*Ratio of drug to excipient 1 103.95 103.95 103.95 14.26 0.01 
Drug*Conc. of drug 1 13.7 13.7 13.7 1.88 0.23 
Excipient*Ratio of drug to excipient 1 218.63 218.63 218.63 30.00 0.00 
Excipient*Conc. of drug 1 71.77 71.77 71.77 9.85 0.03 
Ratio of drug to excipient*Conc. of drug 1 0.02 0.02 0.02 0.00 0.97 
Error 5 36.44 36.44 7.29 
 
  
Total 15 2329.69         
S = 2.69954   R-Sq = 98.44%   R-Sq(adj) = 95.31% 
       
Table 3.4. Table showing reported values of melting and glass transition temperatures of 
indomethacin and naproxen. 
Drug 
Melting point 
(Tm) 
Glass transition 
temperatures (Tg) 
Naproxen 152°C 7°C 
Indomethacin 158°C 42°C 
 
 
 
	  
	  
	  
	  
59 
 
Table 3.5. Table showing zeta potential values of different nanosuspension formulations A). 
Dowfax-2A1 and B). HPMC E15 containing formulations. 
 
 
 
 
 
 
 
 
Drug Excipient 
Ratio of 
drug-to-
excipient 
Zeta 
potential 
(mV) 
Indomethacin HPMC E15 10 to 1 -23.2 
Indomethacin HPMC E15 2 to 1 -4.94 
Naproxen HPMC E15 10 to 1 -19.8 
Naproxen HPMC E15 2 to 1 -5.25 
 
 
 
 
 
 
 
 
 
Drug Excipient 
Ratio of 
drug-to-
excipient 
Zeta 
potential 
(mV) 
Indomethacin Dowfax 2A1 10 to 1 -49.3 
Indomethacin Dowfax 2A1 2 to 1 -59.8 
Naproxen Dowfax 2A1 10 to 1 -56.9 
Naproxen Dowfax 2A1 2 to 1 -68.2 
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Table 3.6. Particle sizes of different formulations after spray drying and storage stability. 
HPMC E15 containing 
formulations  
    
 
Day 1- Particle size  (nm) 
3 month storage- 
Particle size (nm) 
Formulation No. 
Before Spray 
drying  
After Spray 
drying 
% 
Increase 
Particle size 
(nm) 
% 
Increase 
7 335.50 664.30 198.00 660.00 196.72 
8 335.50 630.20 187.84 705.00 210.13 
15 309.10 400.80 129.67 406.70 131.57 
16 309.10 359.40 116.27 399.00 129.08 
      Dowfax 2A1 containing 
formulations 
    
 
Day 1- Particle size  (nm) 
3 month storage- 
Particle size (nm) 
Formulation No. 
Before Spray 
drying  
After Spray 
drying 
% 
Increase 
Particle size 
(nm) 
% 
Increase 
3 223.3 372.3 166.73 1742 780.11 
4 223.3 351.5 157.41 1372 614.42 
11 232 500.3 215.65 2907 1253.01 
12 232 498.3 214.78 3982 1716.37 
 
Table 3.7. Physical properties used for the χ (chi) calculations  
  
Mol wt. 
(g/mol) 
Density 
(g/cm3) 
Molar volume 
(cm3/mol) 
Naproxen 230.26 1.16 198.50 
Indomethacin 357.29 1.33 268.64 
HPMC E15 20227 1.30 15559.23 
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(Note: The density of the amorphous naproxen is unavailable due to the poor physical stability of 
its glass i.e. fast crystallizer, thus approximate value was used for calculations i.e. 3% less that the 
true density of its crystalline counterpart) 
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3.7. Figures: 
 
 
	  
Figure 3.1. Sotax® USP II adapted to hold the dialysis sacs. Top part of each vessel is attached 
with the plastic adapter to hold the dialysis sacs. 
 
 
Figure 3.2.  Assembly of the dialysis sac with the adapter in Sotax® USP II apparatus. 
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Figure 3.3. Schematic representation of the assembly of dialysis sac and its adapter within USP 
apparatus II.  
 
 
Figure 3.4. Plot showing the effect of formulation variables on nanocrystal aggregation during 
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spray drying (y-axis showing mean particle size). 
 
 
Figure 3.5. A plot of the interactions between formulation variables showing dependency of 
nanocrystal aggregation on drug-to-excipient ratio (drug to exp).  
 
 
Figure 3.6. Plot showing the effect of formulation variables on the percent yield during spray 
drying (y-axis showing mean percent yield). 
	  
	  
	  
	  
65 
 
Figure 3.7. Plot showing interactions among formulation variables on the percent yield during 
spray drying. 
 
 
Figure 3.8. Plot showing PXRD of all formulations containing indomethacin. 
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Figure 3.9. Plot showing PXRD of all formulations containing naproxen. 
 
 
Figure 3.10. Dissolution profiles of indomethacin spray dried (SD) formulations containing: A) 
Dowfax-2A1; and B) HPMC E15 excipient. (Note: formulations 3 and 7 were less aggregated 
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compared to formulations 1 and 5, refer to Table 2). 
 
 
Figure 3.11. Dissolution profiles of naproxen spray dried (SD) formulations: A) Dowfax 2A1; and 
B) HPMC E15 containing formulations. (Note: formulations 11 and 15 were less aggregated 
compared to formulations 9 and 13, refer to Table 2). 
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Figure 3.12. DSC plots of physical mixtures of naproxen (A) and indomethacin (B) with Dowfax 
2A1.  
	  
	  
	  
	  
69 
 
Figure 3.13. DSC plots showing physical mixtures of indomethacin (A) and naproxen (B) with 
HPMC E15. 
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Figure 3.14. A plot showing interaction parameter values (slope values) of naproxen-HPMC E15 
and indomethacin-HPMC E15 systems based on melting point depression approach. 
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Figure 3.15. Plot showing PXRD data of all the formulations after three month of storage stability. 
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Chapter 4 
	  
	  
	  
	  
Bulking Agents to Prevent Nano-crystal Aggregation During  
Spray or Freeze Drying  
 
Abstract 
In this study, the effect of small and high molecular weight bulking agents was evaluated 
during spray or freeze-drying of indomethacin nano-crystalline suspension (BCS class II) 
with Dowfax 2A1 as the stabilizer. Particle size, yields and crystallinity of the dried 
crystalline powders with or without bulking agents were determined. Interaction between 
the nanosuspension stabilizer (i.e. Dowfax 2A1) and bulking agents was investigated 
utilizing IR spectroscopy and contact angle measurement. All the formulations containing 
small molecular weight bulking agents were non-aggregating compared to those 
formulations containing polysaccharides during spray or freeze-drying processing of 
indomethacin nano-crystalline suspensions. In addition, higher crystalline powder yields 
were observed with formulations containing higher glass transition temperature bulking 
agents during spray drying. The bulking agents with low glass transition temperatures were 
sticking to the spray drier glass walls and thus resulted in lower yields. The small 
molecular weight bulking agents showed favourable or strong interactions with Dowfax 
2A1 (via IR and contact angle) and this may be the reason of no or minimal nano-crystal 
aggregation during spray or freeze drying. A combination of bulking agent (i.e. small 
molecular weight and polysaccharides) may be utilized to achieve higher spray-drying 
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yields and non-aggregating nano-crystalline powders.   
	  
4.1. Introduction 
Active pharmaceutical ingredients can be classified into four different categories (as per 
the Biopharmaceutics Classification System, Class I - IV) according to their solubility and 
permeability (1). BCS class I drugs have good solubility and permeability; class II drugs 
have good permeability but poor solubility; class III drugs have good solubility but poor 
permeability; and class IV drugs have poor solubility and permeability. In the last two 
decades, 30-40 % of the newly discovered or synthesized chemical compounds have poor 
aqueous solubility and thus poor oral bioavailability (classified under BCS Class II/IV) (2-
5). This problem poses a great challenge to formulators to design and develop 
appropriately soluble and thus orally bioavailable formulations of poorly soluble 
compounds. There are many formulation technologies utilized to increase solubility and/or 
dissolution rate to enhance oral bioavailability. One of the approaches utilized to increase 
dissolution rate is formulation of nano-crystalline suspensions (6, 7).  
In recent years, the popularity of nano-technology has increased tremendously and many 
nano-based formulations are already on the market (8). Nano-crystalline suspensions can 
be described as colloidal dispersions of discrete drug crystals in stabilizer/s solutions of 
aqueous or non-aqueous media. The typical size range for pharmaceutical nanosuspensions 
is 100 - 1000 nm but most of the pharmaceutical nano-crystalline suspensions have sizes 
below 500 nm. There are two different approaches to formulate nano-crystalline 
suspensions: top-down (i.e. mainly grinding or milling from larger size crystals) and 
bottom-up (i.e. mainly precipitation or solvent evaporation from the drug solution). Size 
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reduction significantly increases the specific surface area (or surface area-to-volume ratio) 
and hence dissolution rate as described by the Noyes-Whitney equation (9). Accordingly, 
in case of “dissolution-rate limited” poorly water-soluble drugs, nano-crystalline 
suspensions can significantly enhance the drug dissolution and thus oral absorption.  
Nano-crystalline suspensions can be formulated as solid-dosage forms (i.e. nano-
crystalline powders) to improve the physical and chemical instabilities associated with 
liquid nano-crystalline suspension formulations such as, Ostwald ripening, aggregation etc. 
There are different methods utilized to formulate nano-crystalline powders such as, freeze 
or spray drying of nano-crystalline suspensions (10-16) and spraying of nano-crystalline 
suspensions on the carrier beads (such as sugar beads) followed by drying (17). In case of 
spray and freeze-drying, the material experiences thermal or freezing stress, respectively 
and the stress may affect product performance such as, dissolution performance etc. In 
addition, the drying process brings about concentration of the originally dispersed and 
dissolved materials and this may adversely affect both the physical and chemical stability 
of the formulation. For example, reduction in the solvent volume can lead to a decrease in 
the solubility of the surfactant or stabilizer, resulting in stabilizer precipitation and nano-
crystal aggregation. One of the major problems associated with spray or freeze-drying of 
nano-crystalline suspensions is “nano-crystal aggregation” which leads to poor or 
inappropriate dissolution performance (10, 14, 15). It has been shown that the aggregation 
of nano-crystals during drying is dependent on the drug properties. For example, drugs 
with higher hydrophobicity such as, itraconazole and cinnarizine, resulted in higher 
agglomerates and were harder to disintegrate compared to drugs with lower 
hydrophobicity (14).  Several auxiliary or bulking agents were tested and utilized during 
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spray and/or freeze-drying to prevent nano-crystal aggregation (15, 18). In one study, the 
authors have used un-conventional matrix formers such as, Avicel PH101, Fujicalin, 
Aerosol 200 and Intutec SP1 to prevent nano-crystal aggregation during spray drying (15). 
Typical matrix formers or bulking agents utilized in spray and/or freeze-drying of nano-
crystalline suspensions are: sugars (such as, sucrose and trehalose); sugar alcohol (such as, 
mannitol); and polysaccharides (such as, maltodextrins). There are few reports available 
involving the use of these bulking agents against nano-crystal aggregation, but many cases 
exist where their ability to prevent nano-crystal aggregation is questioned (14, 15, 19-21). 
The aim of this study was to better understand the role of bulking agents or matrix formers 
to prevent nano-crystalline aggregation during the drying processes. In this study, several 
disaccharides, sugar alcohol and polysaccharides were investigated to prevent nano-crystal 
aggregation during spray or freeze-drying of nano-crystalline suspensions. Spray drying 
technology was investigated due to its economy and wide application in the 
pharmaceutical industry and academic settings, whereas freeze-drying was utilized for 
spray drying comparison purposes. Indomethacin (BCS class II) was selected as a model 
compound and Dowfax 2A1 (ionic surfactant, negatively charged) was utilized as the 
stabilizer for the nano-crystalline suspensions. The bulking agents were dissolved in the 
nano-crystalline suspensions and spray or freeze-drying was performed to evaluate their 
role in prevention of nano-crystal aggregation during the drying process. 
 
4.1. Materials 
Indomethacin USP, γ polymorph, was purchased from PCCA (Houston, TX). Dowfax 2A1 
(alkyldiphenyloxide disulfonate) was generously gifted by Dow Chemical Company 
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(Midland, MI). HPLC grade acetonitrile (ACROS chemicals) was purchased form Fisher 
Scientific (Pittsburgh, PA). Hermetic pans and lids were purchased from TA instruments. 
4.2. Methods 
4.2.1. Preparation of indomethacin nanosuspensions 
The indomethacin suspensions were prepared via the top-down approach using a Netzsch 
wet media mill. The required amount of indomethacin (1% w/v or 2%) was suspended in 
the stabilizer solution (Dowfax 2A1, 0.5% w/v or 0.1% w/v) and the suspension was 
stirred to achieve homogenous macro-suspensions. The macro suspensions were milled at 
a milling speed of 2000 rpm in the recirculation mode. The temperature of the suspensions 
was maintained below 25°C during the milling process to prevent any instability issues. 
The milling was performed for 90-120 minutes to achieve the required size of 
indomethacin nano-crystalline suspensions.  
4.2.2. Spray drying of nano-crystalline suspensions 
Indomethacin nano-crystalline suspension formulations were spray dried using a lab scale 
Buchi spray dryer B-190. Briefly, the spray dryer was pre-conditioned at the pre-set 
conditions of aspiration rate (-31 mbar); feed rate (9.3 mL/min) and inlet temperature 
(150°C) using 100 mL of distilled water. The optimized conditions were selected based on 
our previous study. Once the spray dryer was equilibrated, 100 mL of the prepared nano-
crystalline suspension formulations with or without bulking agents were spray dried. Spray 
gas (atomizing air) was maintained at 40 mm Hg (air flow was approximately 600 L/hour) 
for all the formulations. The dried samples were removed from the collection chamber 
using a plastic scraper and evaluated for percent yield, particle size and polymorphic 
changes, if any. 
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4.2.3. Freeze drying of nano-crystalline suspensions 
Indomethacin-Dowfax 2A1 nano-crystalline suspensions (2% w/v Indomethacin– 1% w/v 
Dowfax 2A1) were prepared as described above. Samples were prepared in 5 ml tubing 
glass vials (Wheaten Sciences Products) (2 mL fill volume) and freeze-dried in FTS 
system LyostarTM II (SP scientific). Briefly, the indomethacin nano-crystalline suspensions 
(2% w/v, 1 mL) and different concentrations of bulking agent solutions (5% w/v, 10 w/v 
or 20% w/v, 1 mL) were added to these vials and vortexed to achieve homogenous mixing. 
The shelf temperature during primary drying was set at -40°C (freezing protocol was 5°C: 
15 minutes; -5°C: 15 minutes and -40°C: 2 hours or 14 hours) and increased at 0.1°C to 
40°C for secondary drying and held for 6 hours. All experiments were performed at a shelf 
temperature -40°C unless specified (-60°C in some cases). Chamber pressure throughout 
primary drying was set at 60 mTorr, and in all cases the product temperature was 
maintained below the collapse temperature. Vials were sealed in the chamber under 
vacuum and stored at -20°C until use.  
4.3.4. Particle size analysis 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments) to determine the Z-average (at 90° scattering angle) and PDI of the 
nanosuspensions before and after the drying processes. Briefly, the dried samples were re-
suspended in a saturated and filtered (0.2 µm membrane filter) solution of indomethacin in 
30% glycerin solution to avoid any discrepancy from dissolution of nano-particles during 
measurements. The viscosity of this dispersant solution was measured using a Brookfield 
viscometer (Model DV-III) and this was used to calculate the particle size of the re-
dispersed nano-suspension. Each sample was analyzed in triplicate and the results were 
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reported as the mean values of these runs. 
4.3.5. Determination of percent yield 
For calculation of percent yield, the drug amounts in liquid and dried nano-crystalline 
suspensions were determined using an HPLC-UV method (as described below). Briefly, 
the nano-crystalline suspension formulations were dissolved in the mobile phase and this 
solution was used to quantify the drug amount. The formula used for calculation of the % 
yield was: 
               Equation 4.1 
Note: Drug mass in and out represents, total amount of drug (in the nanosuspensions) that 
was spray dried and that was recovered (dried powder), respectively. 
4.3.6. HPLC-UV method 
The standard curve of indomethacin was generated using a Perkin-Elmer HPLC system 
(series 200) connected to a UV-Vis detector (Perkin-Elmer 785). The amount of 
indomethacin was quantified using a C-18 Zorbax® column (Waters Corporation, USA) 
and the mobile phase was a mixture of two phases (A/B) at a 50:50 v/v ratio. Phase A was 
a mixture of water and phosphoric acid (0.2% v/v) and phase B was acetonitrile. The flow 
rate was maintained at 1.3 ml/min and the UV absorbance was measured at 237 nm. 
Various dilutions were made in the mobile phase to prepare a standard curve. The 
concentration range for linearity was 0.005 mg/ml to 0.2 mg/ml with an R2 value of 0.99.  
4.3.7. Differential scanning calorimetry 
DSC was performed using a TA Q1000 calorimeter (TA instruments, New Castle, DE, 
% Yield = Drug Mass Out ×
100
Drug Mass In
%!
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USA) equipped with a refrigerated cooling accessory. The instrument was calibrated for 
enthalpy and heat capacity using indium and sapphire, respectively. Approximately 5-10 
mg of the spray dried samples were sealed in hermetic pans and analyzed. The heating rate 
was maintained at 5°C/min from room temperature to 180°C. Nitrogen gas was used for 
purging at a flow rate of 50 ml/min. Data were analyzed using TA universal analysis 
software. 
4.3.8. Powder X-ray diffraction (PXRD) 
PXRD (powder X-ray diffraction) was used to study the crystallinity of the dried samples. 
X-ray diffraction patterns were obtained using an X-ray diffractometer (Model D5005, 
Bruker AXS Inc., Madison, WI) using Cu-kα radiation, a voltage of 40 kV, and a current 
of 40 mA. All the scans were performed at a scan rate of 2°/minute with steps of 0.02° 
from 5° to 50° at 2θ angle. 
4.3.9. Attenuated total reflectance- Fourier transform IR spectroscopy (ATR-FTIR) 
IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific) 
spectrometer attached with an attenuated total reflectance (ATR) accessory. All bulking 
agents were freeze-dried with or without Dowfax 2A1 solution (ratio of bulking agents-to-
Dowfax 2A1: 10 to 1) as described in the freeze-drying section above.  Freeze-dried 
powders were placed on the crystal window (Germanium) and compressed lightly using 
the pressure clamp. Spectra were recorded over a range of 400–4000 cm−1 with a 
resolution of 4 cm−1, for 128 parallel scans. Data analysis was performed on Omnic® 6.0a 
software (Thermo Nicolet Corporation). 
4.3.10. Stability studies 
All the spray-dried formulations (with and without auxiliary excipients) were stored at 4°C 
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and 25°C for 6 months in closed vials. The spray-dried samples were analyzed for particle 
size, powder XRD and DSC. 
4.3.11. Contact angle measurement 
All bulking agents were spray dried at a concentration of 10 % w/v and secondary vacuum 
drying was performed for 24 hours at room temperature. The spray-dried powders 
(approximately 150 mg) were compressed using a Carver press at a pressure of 5 tons for 2 
minutes, after which the pellet was carefully removed from the die. The pellets were 
vacuum dried overnight at room temperature to remove any adsorbed moisture during 
processing. The dried pellets were utilized to measure contact angle with Dowfax 2A1 
solution (approximately 40-50%) or distilled water. The contact angle was measured using 
a contact angle goniometer. A drop of 2.5 µl of Dowfax 2A1 or distilled water was selected 
for measurement. All measurements were performed in triplicate and the mean values were 
reported. 
 
4.4. RESULTS 
4.4.1. Effect of bulking agents on nano-crystal aggregation during spray drying 
To evaluate the effect of different bulking agents (or matrix formers), spray drying was 
performed as described under the methods section. Different amounts of bulking agents 
were dissolved in the indomethacin nano-crystalline suspensions (1% w/v Indomethacin – 
0.5% w/v Dowfax 2A1) before spray drying processing. The ratios of drug-to-bulking 
agent in the formulations were: 1 to 2.5, 1 to 5 or 1 to 10 w/w. As shown in Figure 4.1, all 
small molecular weight bulking agents (such as, disaccharides and sugar alcohol) were 
able to protect the nano-crystals from aggregating during spray drying with no statistical 
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difference over the concentration range investigated (i.e. 2.5 – 10% w/w). In the case of the 
high molecular weight bulking agents (i.e. maltodextrins and Ficoll PM 70), large size 
nano-crystal agglomerates were observed (Figure 4.2). Nano-crystal aggregation of 
formulations containing Ficoll PM70 was comparatively low compared to those containing 
maltodextrins. 
4.4.2. Effect of bulking agents on spray-dried powder yields  
The recovery or percent yield of the spray-dried powder was calculated as described under 
the methods section. The yield of the spray-dried powders varied from 20% w/w to 65% 
w/w during spray drying processing. To understand the percent yield with different bulking 
agents, a plot of the glass transition temperatures (Tg) of the bulking agents (reported 
values) and spray drying percent yields was plotted as shown in Figure 4.3. A correlation 
was observed between the percent yield and the glass transition temperature. The 
formulations containing bulking agents with lower Tg (such as sucrose and maltose) had 
lower yields compared to those formulations containing bulking agents with higher Tg 
(such as lactose, trehalose, Ficoll PM70, Maltodextrin DE 4-7 and maltodextrin DE 16.5-
19.5). 
4.4.3. Characterization of spray-dried nano-crystal powders 
4.4.3.1. Differential scanning calorimetry 
All the bulking agents, except mannitol were amorphous after spray drying processing and 
no polymorphic changes were observed for indomethacin in any formulation (Figure 4.4). 
4.4.3.2. Powder-X-ray diffraction 
Powder X-ray diffraction was performed on the spray-dried nano-crystalline powders. 
Indomethacin remained crystalline before and after spray drying processing, whereas all 
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the bulking agents were amorphous, except mannitol as shown in Figure 4.5. In case of 
mannitol, the X-ray diffraction patterns correspond to the β form of crystalline mannitol. 
4.4.4. Storage stability  
Indomethacin nano-crystalline suspensions (approximately 180 nm) were prepared and 
spray drying was performed (ratio of drug-to-bulking agent 1 to 5 w/w) as described in the 
methods section. All spray dried formulations were stored at 4°C and 25°C for 6 months in 
closed vials. All the formulations containing small molecular weight bulking agents were 
stable and showed no further aggregation. In the case of maltodextrin containing 
formulations, further aggregation was observed at 25°C. No polymorphic changes were 
observed in any of the spray-dried powders (data not shown). 
4.4.5. Freeze drying of indomethacin nano-crystalline powders 
Two indomethacin nano-crystalline suspension formulations with different concentrations 
of Dowfax 2A1 were prepared and freeze-dried as described in the method section. As 
shown in Table 4.2 and Figure 4.6, the formulations containing small molecular weight 
sugars were non-aggregating compared to those containing polysaccharides. Indomethacin 
nano-crystal aggregation in the Ficoll PM70 containing formulation was low compared to 
those formulations containing maltodextrins. In addition, all the formulations were tested 
with different freezing steps (i.e. 2 hours and 14 hours) for the primary drying step. In case 
of 1% Indomethacin-0.1% Dowfax 2A1, the longer freezing step (i.e. 14 hours) resulted in 
larger aggregates compared to the shorter freezing step (i.e. 2 hours) as shown in Figure 
4.7A. In the case of 1% w/v Indomethacin-0.5% w/v Dowfax 2A1, minimal aggregation 
was observed with or without all the bulking agents and no differences were observed with 
the different freezing steps (Figure 4.7B). In addition, all these formulations were tested 
	  
	  
	  
	  
85 
with an additional freeze-drying annealing step (- 10°C) or with a - 60°C freezing step but 
no difference in indomethacin nano-crystal aggregation was observed compared to freeze-
drying performed at  - 40°C (data not shown). 
4.4.6. ATR-FTIR spectroscopy 
Freeze dying of the stabilizer (Dowfax 2A1) and bulking agents was performed to 
understand any interactions between them. As shown in Figure 4.8, the C-H functional 
group IR region of the small molecule bulking agents with Dowfax 2A1 showed marked 
differences compared to those of the polysaccharides-Dowfax 2A1 freeze dried samples. 
4.4.7. Contact angle measurement 
To determine the interaction between the bulking agents and Dowfax 2A1, contact angle 
measurements were performed. As shown in Table 4.3, the contact angle between Dowfax 
2A1 and polysaccharides was higher compared to small molecular weight bulking agents. 
In addition, the contact angle of the bulking agents with distilled water is given for 
comparison. 
 
4.5. DISCUSSION 
In this study, the role of bulking agents on the aggregation of nano-crystalline suspensions 
of the poorly soluble drug indomethacin during spray or freeze-drying processing was 
explored. All small molecular weight bulking agent-containing nano-crystalline 
formulations were non-aggregating during both spray and freeze-drying processing. The 
maltodextrin containing formulations showed aggregation during both spray and freeze-
drying. However, Ficoll PM70 showed aggregation during spray drying (smaller 
aggregates compared to the maltodextrins) but no or minimal aggregation during freeze-
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drying. FTIR spectroscopy was utilized to understand the interaction between Dowfax 2A1 
and the bulking agents. As shown in Figure 4.8, small molecular weight bulking agents and 
Dowfax 2A1 mixtures (freeze-dried samples) showed changes in the C-H region, which 
suggests that these molecules have favorable interactions (such as hydrogen bonding, ionic 
interaction etc.), which might be responsible for nano-crystal size preservation. However, 
higher molecular weight bulking agents (such as maltodextrins or Ficoll PM70) with 
Dowfax 2A1 (freeze-dried sample) did not show any change in the C-H IR region, 
indicating no or minimal interaction and this may be responsible for the nano-crystal 
aggregation observed during spray or freeze-drying. In addition, as shown in Table 4.3, all 
small molecular weight bulking agents showed lower contact angle with Dowfax 2A1 
compared to the polysaccharides. This suggests wetting of the small molecular weight 
bulking agents by Dowfax 2A1 solution is superior compared to that of the 
polysaccharides, which again may be due to favorable interactions (as observed via FTIR). 
Since, the indomethacin nano-crystals are surrounded by Dowfax 2A1 surfactant 
molecules, the interaction between Dowfax 2A1 and the bulking agent (or matrix former) 
appears to play an important role in nano-crystal preservation during the drying processes. 
Ficoll PM70 prevented nano-crystal aggregation only during freeze-drying (and there was 
no or minimal interaction with Dowfax 2A1 as indicated via IR spectroscopy and contact 
angle measurement). This suggests Ficoll PM70 has different mechanism of nano-crystal 
preservation during freeze-drying, which may be attributed to one or more of these 
properties: preferential exclusion, surface activity and/or increased solution viscosity 
limiting as reported by (20).  
Over the Dowfax 2A1 concentration range investigated the extent of aggregation of the 
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freeze-dried formulations with no bulking agents and formulations containing 
maltodextrins showed dependency on the Dowfax 2A1 concentrations with less 
aggregation at higher Dowfax 2A1 concentration. Generation of new surfaces (ice crystal 
surface) during freeze-drying may cause surfactant molecules to re-distribute to these new 
interfaces. Such re-distribution may lead to reduced surfactant concentrations at the drug 
crystal surface in formulations containing low concentrations of Dowfax 2A1 thus 
resulting in higher aggregation.  
In addition, it was observed that the spray-drying yield of the nano-crystalline powders 
was dependent on the glass transition temperature of the bulking agents (Figure 3). The 
reason for the lower yield for formulations containing low Tg bulking agent is considered 
to be due to sticking of the particles on to the spray dryer walls as a result of their rubbery 
state as previously reported. 
 
4.6. CONCLUSIONS 
Low molecular weight bulking agents are better in preventing nano-crystal aggregation 
during spray or freeze-drying processing due to favorable interactions between them and 
the stabilizer Dowfax 2A1, as observed via FTIR and contact angle measurement. All 
spray-dried nano-crystal formulations containing small molecular weight bulking agents 
were stable over a 6-month storage period. Higher spray-dried powder yields were 
observed for formulations containing bulking agents with higher glass transition 
temperatures due to less sticking inside the spray dryer glass walls. A combination of low 
molecular weight bulking agents and high molecular weight polysaccharides may be 
utilized to achieve higher yield and non-aggregating nano-crystals during spray drying. 
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Indomethacin nano-crystal formulations with low concentrations of Dowfax 2A1 resulted 
in higher aggregation during freeze-drying processing. Favorable interactions between 
bulking agent and nano-crystalline suspension stabilizers are required to achieve non-
aggregated spray or freeze-dried nano-crystal powders.  
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4.7. Tables 
Table 4.1. Particle size of spray-dried powders stored at different temperatures for 6 months. 
Indomethacin 1% w/v-
Dowfax 2A1 0.5% w/v 
(Spray dried with 
bulking agents) 
After spray drying 
Spray dried 
powders stored for 
6 months at 4°C 
Spray dried 
powders stored for 
6 months at 25°C 
Z average PDI Z average PDI  Z average PDI  
No bulking agent 1473 0.424 1496 0.557 1865 0.29 
Sucrose 178.6 0.218 173.8 0.205 174.1 0.199 
Trehalose 180.5 0.179 175.6 0.186 174.9 0.197 
Lactose 184.7 0.211 178.4 0.231 173.4 0.185 
Maltose 179.1 0.193 175.6 0.205 178.5 0.188 
Mannitol 201.7 0.216 191.1 0.211 189.1 0.199 
Maltodextrin DE16.5 514.6 0.697 520.9 0.744 541 0.587 
Maltodextrin DE4-7 718.7 0.47 743.3 0.717 851.6 0.761 
Ficoll PM70 210 0.244 211 0.232 214 0.22 
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Table 4.2. The effect of bulking agents on nano-crystal aggregation during freeze-drying. 
Bulking agent 
Indomethacin 1% w/v - 0.5% 
Dowfax 2A1 
Indomethacin 1% w/v - 0.1% 
Dowfax 2A1 
Before freeze 
drying 
After freeze 
drying 
Before freeze 
drying 
After freeze 
drying 
No bulking agent 197.6 334.2 222.4 1216 
Sucrose 197.6 208 222.4 223.3 
Lactose 197.6 211.7 222.4 236.5 
Trehalose 197.6 223.2 222.4 232.4 
Mannitol 197.6 227.7 222.4 232.5 
Maltodextrin DE 4-7 197.6 261.6 222.4 438.4 
Maltodextrin DE 16.5-19.5 197.6 230.6 222.4 443.8 
Ficoll PM70 197.6 210 222.4 229.7 
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Table 4.3. Contact angle between bulking agent (tablet) and Dowfax 2A1 (as solvent). 
 Contact angle (°θ) 
Bulking agent 
Dowfax 2A1 solution 
(40-50%) Water (pure) 
Sucrose 51.7 21.6 
Trehalose 45.7 24.2 
Maltose 53.45 21  
Lactose 58.5 23.5 
Mannitol 48.75 34 
Maltodextrin DE4-7 98.15 31.5 
Maltodextrin DE16.5 74.35 27 
Ficoll PM70 97.65 25.8 
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4.7. Figures 
	  
	  
	  
	  
 
Figure 4.1. A plot showing the effect of bulking agents (small molecular weight) on indomethacin 
nano-crystal aggregation.   
 
 
Figure 4.2. A plot showing the effect of bulking agents (polysaccharides) on indomethacin nano-
crystal aggregation.   
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Figure 4.3. A plot showing the effect of bulking agents on spray-dried powder yields. 
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Figure 4.4. DSC thermograms showing the crystallinity of indomethacin and bulking agents (A: 
lactose; B: maltose; C: mannitol; D: sucrose; E: trehalose; F: maltodextrin DE16.5; G: maltodextrin 
DE4-7 and H: ficoll PM70 containing spray-dried powders). 
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Figure 4.5. PXRD of spray-dried powders (A: small molecular weight and B: polysaccharides 
containing formulations at drug-to-bulking agents: 1 to 5). 
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Figure 4.6. A plot showing the effect of bulking agents on nano-crystal aggregation during freeze-
drying. 
 
Figure 4.7A. A plot showing the effect of bulking agents on nano-crystal aggregation (1% w/v 
indomethacin-0.1% w/v Dowfax 2A1) with 2 or 14 hours of freezing step during freeze-drying. 
 
 
Figure 4.7B. A plot showing the effect of bulking agents on nano-crystal aggregation (1% w/v 
indomethacin-0.5% w/v Dowfax 2A1) with 2 or 14 hours of freezing step during freeze-drying. 
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Figure 4.8. IR spectra of freeze-dried bulking agents with or without Dowfax 2A1 (A: sucrose; B: 
lactose; C: maltose; D: trehalose; E: mannitol; F: ficoll PM70; G: maltodextrin DE4-7 and H: 
maltodextrin DE16.5). Arrow indicates differences in the C-H IR region. 
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Chapter 5 
	  
	  
	  
	  
Wet Milling Induced Physical and Chemical Instabilities of Naproxen Nano-
Crystalline Suspensions 
	  
	  
	  
	  
Abstract 
	  
Wet milling is the most common approach to formulate nano-crystalline suspensions. The 
effect of high intensity wet milling on the physical and chemical stability of a poorly 
soluble drug was investigated. Naproxen (1% w/v) was suspended in two different 
stabilizers (i.e. HPMC E15 and Tween 80) and stabilizer concentrations (0.2% or 0.6% 
w/v) in distilled water. Wet milling was performed at two different speeds (i.e. 3400 rpm 
and 2000 rpm) for four continuous hours. The milled samples were analyzed for physical 
and chemical instabilities. Wet milling of naproxen-HPMC E15 at high milling intensity 
caused both physical and chemical instabilities as observed by particle size measurement 
and chemical analysis, respectively. The naproxen-Tween 80 formulations were stable 
regardless of milling intensity. Naproxen-HPMC E15 wet-milled samples, showed an IR 
peak shift suggesting strong bond formation or molecular interaction (i.e. amorphous 
phase). In addition, naproxen has a strong interaction with HPMC E15 as determined by 
MTDSC (i.e. melting point depression). The generation of amorphous phase at the 
naproxen-HPMC E15 crystal surface may be responsible for both aggregation and 
degradation during wet milling. Decarboxylated naproxen was identified as a degradation 
product. Milling intensity and/or selection of stabilizer/s are crucial for the stability of 
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nano-crystalline suspensions.  
	  
	  
5.1. Introduction 
Active pharmaceutical ingredients can exist in different solid-state forms: crystalline 
polymorphs, defected crystals and amorphous. These solid-state forms have different 
energetics that in turns lead to different physical and chemical properties [1, 2, 3, 4]. 
Crystalline polymorphs have different packing arrangements of the same molecules and 
amorphous solids have long-range three-dimensional packing disorders [4, 5]. Conversion 
from one solid-state to another (i.e. polymorph or amorphous transformation) requires 
passing through a thermodynamic energy barrier and involves a discontinuous change in 
free energy [5].  In addition, crystalline polymorphs have different energy states and the 
energy of the system increases or decreases depending on the solid-state transformation. 
Introduction of crystal defects and/or amorphous formation results in an increase in Gibbs’ 
free energy as well as an increase in free volume and thus results in thermodynamic 
instability.  
The number of poorly soluble drug candidates coming out of drug discovery has increased 
tremendously over the past 20 years or so [6, 7, 8, 9, 10]. One of the approaches to increase 
solubility and thus oral bioavailability is to produce nano-crystalline suspensions. Milling 
(wet and dry) is the most common unit operation utilized to reduce particle size in 
pharmaceutical manufacturing. Milling induces defects and/or solid-state transformation, 
which in turn may affect material properties such as solubility and thus may alter 
bioavailability. There have been many literature reports on solid-state transformation 
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during dry milling [11, 12, 13, 14] and also a few reports related to wet milling [15]. Wet 
media milling is widely utilized to form nano-crystalline suspensions to improve the 
dissolution rate of BCS (Biopharmaceutical classification system) class II/IV compounds. 
High intensity mills and relatively long milling processing times (sometimes up to 24 
hours) are generally required [16] to produce nano-crystalline suspensions. During this 
process, mechanical energy is applied (i.e. collisions such as drug-drug, drug-chamber and 
drug-milling beads), which in turn generates strain on the crystal lattice and thus results in 
particle size reduction. The applied mechanical stress or strain can cause crystal defects 
and/or formation of amorphous phase. Amorphous regions or crystal defects are 
undesirable due to their high reactivity, which can lead to further chemical and/or physical 
instability such as nano-crystal aggregation, drug degradation, unstable formulations and 
polymorph conversion [17]. Solid-state transformation during the wet milling process may 
depend on the formulation (excipient/stabilizer, pH, buffering species etc.) and/or 
processing (processing time, temperature, milling intensity etc.) conditions. Appropriate 
stabilizer selection for wet milling is crucial for nano-crystalline suspension stability and 
performance. Not many studies are available which focuses on the effect of different 
stabilizer on the wet milling of poorly soluble drugs. 
In this case study, physical and chemical instabilities of naproxen (a poorly soluble drug) 
are investigated following low and high wet milling intensity in the presence of HPMC-
E15 (polymeric stabilizer) or Tween-80 (small molecular surfactant). Naproxen is 
categorized as a non-steroidal anti-inflammatory drug (NSAIDs). HPMC-E15 and Tween 
80 are non-ionic stabilizers widely utilized for nano-crystalline suspension formulations. 
The influence of wet milling (i.e. Netzsch media mill) intensities in the presence of two 
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different excipients and concentrations were evaluated.  
	  
	  
	  
5.2. Materials  
Crystalline naproxen was purchased from Fagron (Gallipot®). HPMC E15 was purchased 
from Dow Chemicals. Tween 80 and LC-MS grade solvents were purchased from Fisher 
Scientific (Pittsburgh, PA).  Hermetic pans and lids were purchased from TA instruments. 
	  
	  
5.3. Methods 
5.3.1. Wet media milling 
Briefly, naproxen (1% w/v) was suspended in the required amount of stabilizer solution in 
distilled water (either 0.2% w/v or 0.6% w/v) using a magnetic stirrer. The prepared 
macro-suspension was milled using a Netzsch® media mill at different processing 
conditions i.e. milling intensity. The chamber and milling media has a coating of 
zirconium oxide to provide high-energy efficient milling and low contamination from the 
metal parts during the attrition process. The macro-suspensions were milled either with 
HPMC E15 or Tween 80 at two different drug-to-stabilizer ratios i.e. 1:0.2 and 1:0.6. The 
concentration of the drug was kept constant at 10 mg/ml in macro-suspensions and milled 
for 4 hours either at low (i.e. 2000 rpm) or high (i.e. 3400 rpm) milling intensity. The 
milled samples were collected every 15 minutes and analyzed for change in particle size 
and chemical degradation.  
5.3.2. Dry milling 
5.3.2.1. Ball-milling 
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A Retsch MM330 ball mill was utilized. Briefly, 3 grams of sample (i.e. mixtures of 
naproxen-HPMC E15 at 1:0.6 ratio) was filled into the milling chamber. The sample was 
milled for 2 hours (30 milling minutes and 10 minutes wait time) at a frequency of 20/sec. 
The milled samples were analyzed for chemical degradation, powder X-ray diffraction and 
FTIR.  
5.3.2.2.Cryo-milling 
A Freezer mill (SPEX SamplePrep) 6750 was utilized. Approximately 3 grams of sample 
(i.e. naproxen-HPMC E15 at 1:0.6 ratio) was filled into the milling chamber. Liquid 
nitrogen was used as a cryogenic liquid. The milling chamber and the instrument were pre-
chilled with the liquid nitrogen before milling processing. The sample was processed for 2 
hours (2 minutes cooling and 2 minutes milling) at the highest frequency. The milled 
samples were analyzed for chemical degradation, powder X-ray diffraction and FTIR.  
5.3.3. Solid-state characterization 
5.3.3.1.Particle size analysis 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments). Briefly, the samples were suspended in a saturated and filtered (0.2 µm 
membrane filter) solution of naproxen in 30% glycerin. Each sample was analyzed in 
triplicate and the results were reported as the mean value. 
5.3.3.2.Powder X-ray diffraction 
PXRD (powder X-ray diffraction) was used to evaluate sample crystallinity. Diffraction 
patterns were obtained using an X-ray diffractometer (Bruker AXS Model D2 Phase 
diffractometer, Germany) using Cu-kα radiation (30 kV voltage and 10 mA current). All 
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scans were performed at 1°/min from 5° to 40° 2θ angles.  
5.3.3.3. Attenuated total reflectance- Fourier transform IR spectroscopy (ATR-FTIR) 
IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific) 
spectrometer attached with an attenuated total reflectance (ATR) accessory. For solid 
samples (i.e. dry milled samples), powders were placed on the crystal window 
(Germanium) and compressed lightly using the pressure clamp. In case of liquid samples 
(i.e. milled suspension), the samples were centrifuged to separate the drug (as tiny pellets) 
from the distilled water. The supernatant was decanted off and drug pellets were vacuum 
dried and then analyzed as solid samples. Spectra were recorded over a range of 400–
4000 cm−1 with a resolution of 4 cm−1, for 128 parallel scans. Data analysis was performed 
on Omnic® 6.0a software (Thermo Nicolet Corporation).  
5.3.3.4. Modulated differential scanning calorimeter (MDSC) 
A TA instrument Q1000 calorimeter (TA instruments, New Castle, DE, USA) connected to 
RCS90 cooling accessory was utilized for analysis. The instrument was calibrated for 
enthalpy and heat capacity using indium and sapphire, respectively. In case of wet milled 
samples, the suspension were centrifuged to separate the drug as pellet. The drug pellets 
were dried under vacuum and the pellets were utilized for DSC. About 5 - 10 mg of 
samples were hermetically sealed and analyzed. Nitrogen was used as a purging gas; at a 
flow rate of 50 ml/min. Samples were heated at 2°C/min at an amplitude of +/- 0.82°C 
with a period of 80 seconds. Data were analyzed using TA universal analysis software.  
5.3.4. Chemical characterization 
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5.3.4.1.HPLC-UV analysis 
To assess the chemical degradation following wet milling processing, an HPLC-UV 
method was developed. The concentration of naproxen was determined using a Perkin 
Elmer HPLC system (series 200) with a UV absorbance detector (Perkin Elmer) set at 270 
nm. The mobile phase was acetonitrile/0.1% trifluoroacetic acid (50/50, v/v).  A Waters® 
C18 symmetry column (4.6 mm×150 mm, 5 µm) was used with the flow rate set at 1 
ml/min and the temperature set at 30°C. The chromatographs were analyzed using a 
PeakSimpleTM Chromatography System.  
5.3.4.2.LC-MS analysis 
The detection was performed using a Shimadzu LCMS 2020 single quadrupole mass 
spectrometer system attached to a Shimadzu prominence Ultra Fast-LC. High purity 
nitrogen gas was used as the nebulizer gas at 10 liters/min. The mobile phase was a 
mixture of methanol and 0.1% formic acid containing water (90/10, v/v) at a flow rate of 
0.2 µl/min. Electrospray ionization was operated in the positive ion mode. MS full ion. 
 
5.4. Results 
5.4.1. Naproxen wet milling with Tween 80 or HPMC E15 
Wet milling was performed on naproxen-Tween 80 and naproxen-HPMC E15 macro-
suspension formulations. Two different macro-suspension formulations with 1% w/v 
naproxen were prepared using either 0.2% w/v or 0.6% w/v excipient solutions. These 
formulation were milled at either low i.e. 2000 rpm or high i.e. 3400 rpm intensity for four 
hours continuously. During milling, suspension samples were collected from the milling 
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chamber and analyzed for particle size and chemical analysis. In the case of naproxen-
Tween 80 milled suspensions, the formulations were both physically (particle size) and 
chemically (data not shown) stable at all excipient concentrations and milling intensities 
investigated. These naproxen-Tween 80 nano-suspension formulations were approximately 
300 nm in size (Table 5.1).  
In case of naproxen-HPMC E15 nano-suspension formulations, the particle size decreased 
to a minimum (approximately 300 nm) at or around 60 minutes. Prolonged milling (more 
than 60 minutes) caused an increase in particle size due to aggregation. Interestingly, the 
increase in particle size with naproxen-HPMC E15 nano-suspensions was only observed at 
the higher milling intensity i.e. 3400 rpm. Both drug formulations (i.e. 1% w/v drug-0.2% 
w/v HPMC E15 and 1% w/w drug-0.6% w/v HPMC E15) showed an increase in particle 
size with prolonged milling at 3400 rpm regardless of excipient concentration (Figure 5.1). 
In addition, the naproxen-HPMC E15 wet milled samples (at 3400 rpm milling intensity) 
were chemically unstable as indicated by the presence of degradation peaks (Figure 5.2) 
when analyzed using HPLC. The percent degradation following four hours of continuous 
milling was approximately 6-8% w/w. These milled formulations were slightly yellow in 
color. The physical (aggregation) and chemical instabilities (drug degradation) associated 
with the milling process appear to be dependent on the HPMC E15 (i.e. stabilizer), as no 
instability issues were observed in case of Tween 80 containing formulations under the 
same milling conditions. 
5.4.2. Dry milling of naproxen with HPMC E15 
To further investigate naproxen degradation in the presence of HPMC E15 under aqueous 
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conditions (at high milling intensity), dry milling of naproxen and HPMC E15 were 
performed. The physical mixture of naproxen and HPMC E15 was prepared at the highest 
HPMC concentration (drug-to-HPMC ratio of 1:0.6) and high intensity ball or cryo-milling 
were performed. Following dry milling, the samples were analyzed for chemical stability. 
No drug degradation was observed with dry milling processing with or without HPMC E15 
(data not shown). This suggests that the chemical instability associated with naproxen-
HPMC E15 nano-suspensions during wet milling requires the presence of water.  
5.4.3. Characterization of wet milled formulations- Differential scanning calorimetry 
In the case of naproxen-Tween 80 wet milled formulations, a reduction in enthalpy was 
observed with increased milling time as shown in Figure 5.3A. The DSC thermograms 
were similar for naproxen-Tween 80 formulations milled at both intensities (i.e. 2000 or 
3200 rpm) and excipient concentrations (the 3200 rpm milled sample data are shown in 
Figure 5.3A). In the case of naproxen-HPMC E15 formulations wet milled at 2000 rpm, 
the DSC results were similar to those of naproxen-Tween 80 formulations i.e. reduction in 
enthalpy with increased milling time (data not shown). Interestingly, in case of the 
naproxen-HPMC E15 formulation wet milled at the higher milling intensity (i.e. 3200 
rpm), the drug melting peak shape was changed drastically with the milling time (Figure 
5.3B) and low enthalpies were observed compared to Tween 80 formulations. 
5.4.4. Characterization of wet milled formulations- ATR-FTIR spectroscopy 
In order to obtain a control for comparisons with wet milled sample, ball milling of 
naproxen was performed. It was observed (Figure 5.4) that ball milling of naproxen alone 
caused small peak shifts (approximately 2 cm-1) towards higher intensity in almost the 
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entire IR region (naproxen carboxyl stretching peak ~ 1726 cm-1 after ball milling is also 
shown, magnified region in Figure 5.4). No further changes were observed with prolonged 
milling. The milled naproxen was utilized as a control for comparison with wet milled 
samples i.e. nano-crystalline suspension formulations.  
FTIR analysis of the wet milled samples (i.e. naproxen-HPMC E15 and naproxen-Tween 
80) was performed to understand drug degradation during the wet milling process. In the 
case of naproxen-HPMC E15 suspensions wet milled at higher wet milling intensity, a 
further peak shift towards higher IR intensity (i.e. blue shift, 1728 cm-1 to 1730 cm-1) was 
observed specially in the vibrational regions of the naproxen hydrogen bonded carboxylic 
acid moiety (1726 cm−1 region) (Figure 5.5). In the case of naproxen-HPMC E15 
suspensions wet milled at 2000 rpm, no peak shift was observed (Figure 5.6). FTIR spectra 
of naproxen-HPMC E15 wet milled at 2000 and 3200 rpm are shown in Figure 5.7 for 
comparison. No peak shift was observed for the naproxen-Tween 80 samples wet milled at 
higher and lower milling intensities (the sample milled at 3200 rpm is shown in Figure 
5.8). To understand peak shifting in the case of naproxen-HPMC E15 wet milled at 3200 
rpm, naproxen was ball-milled or cryo-milled (i.e. dry milling) with HPMC E15 at 1:0.6 
w/w drug-to-HPMC ratio (highest excipient concentration) and the samples were analyzed 
by PXRD and FTIR. ATR-FTIR data of the dry milled samples with naproxen-HPMC E15 
(as physical mixture) were similar (no change in peak position) to those of naproxen alone 
(Figure 5.9). Further, powder X-ray diffraction of all dry milled samples showed x-ray 
diffraction peaks of crystalline naproxen (Figure 5.10). No chemical degradation was 
observed in any samples (data not shown). 
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5.4.5. Interaction between naproxen and HPMC-E15: MTDSC 
Modulated temperature DSC was performed to analyze the molecular interaction between 
naproxen and HPMC E15. As shown in Figure 5.11, increasing the concentration of 
HPMC E15 in naproxen (as physical mixtures) caused a depression in the naproxen 
melting point. This suggests strong interaction between naproxen and HPMC E15 at the 
molecular level.  
5.4.6. Identification of naproxen degradation: LC-MS 
To identify the degradation product during wet milling of naproxen-HPMC E15 
suspension, LCMS analysis was performed. Wet milled samples (milled at higher 
intensity) were analyzed for chemical degradation. The degradation product peak appeared 
at 208 m/z ratio and the peak intensity of the degradation product increased with increasing 
milling time (Figure 5.12). The 208 m/z ratio may correspond to the sodium adduct of the 
decarboxylated product of naproxen as shown in Figure 5.13. Decarboxylation is the most 
common degradation pathway observed in the case of naproxen [18]. 
 
5.5. DISCUSSION 
In this study, the effect of high intensity wet milling of naproxen was investigated with two 
different stabilizers i.e. Tween 80 or HPMC E15. The naproxen-HPMC E15 nano-
crystalline suspension formulations milled at higher milling intensity (i.e. 3400 rpm) were 
not stable and particle size increased during the milling process compared to the Tween 80 
containing formulations (Tables 5.1 and 5.2). Milling intensity was crucial for the stability 
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of the nano-crystalline suspensions, as instability was observed only at high milling speed 
in HPMC E15 containing formulations (i.e. 1% w/v drug-0.2% w/v HPMC E15 and 1% 
w/w drug-0.6% w/v HPMC E15). In addition, HPLC-UV analysis of naproxen-HPMC E15 
wet milled samples (at 3400 rpm) showed the presence of degradation peaks (Figure 5.2), 
which were identified as decarboxylated naproxen (via LCMS). The naproxen-Tween 80 
nano-crystalline formulations were both physically and chemically stable at both milling 
intensities investigated. This suggests that physical (aggregation) and chemical instabilities 
(drug degradation) associated with the milling process appear to be dependent on the 
presence of HPMC E15 as well as the milling intensity. Ball and cryo-milling (dry milling) 
of naproxen with or without HPMC E15 was performed and no drug degradation was 
observed. This suggests that naproxen degradation requires the presence of an aqueous 
environment. 
In case of naproxen-HPMC E15 suspensions milled at 3200 rpm, the DSC thermograms of 
the wet milled samples suggested amorphous formation or surface interaction between 
naproxen and HPMC E15. In addition, naproxen-HPMC E15 wet milled samples prepared 
at higher intensity, showed blue shifts in the vibrational regions of the naproxen hydrogen 
bonded carboxylic acid moiety (1728 cm−1 region) as shown in Figures 5.5 and 5.7. These 
shifts occur as a result of increase in the stretching force constant and indicate the 
formation of strong bonds. This can be explained by considering the effect of 
intermolecular interaction between the amorphous naproxen and the HPMC E15 under 
aqueous conditions. Crystalline naproxen exists as a catemer (unlike its other family 
members such as ibuprofen that exist as a dimer), where one naproxen molecule interacts 
with two other neighboring molecules via intermolecular hydrogen bonding [19]. High 
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milling intensity and/or specific interaction with excipients (such as, HPMC-E15) may 
induce surface amorphization, which may lead to disruption of the naproxen crystal lattice. 
The amorphous phase (or co-amorphous naproxen-HPMC E15) has higher reactivity that 
can lead to chemical degradation. In addition, the DSC thermograms showed the melting 
point depression of naproxen to lower temperatures with increasing concentrations of 
HPMC E15 (in physical mixtures) (Figure 5.11). These results suggest strong molecular 
interaction between naproxen and HPMC E15. This strong interaction and the higher 
milling intensity may cause naproxen amorphization and thus physical and/or chemical 
instabilities. Sharma et al. have observed similar effects in the case of indomethacin-PVP 
nano-crystalline suspensions [15]. Moreover, intermolecular interaction between naproxen 
and HPMC E15 would stabilize the amorphous phase present at the nano-particle surface. 
The increase in naproxen-HPMC E15 nano-suspension particle size and the peak shift 
following wet milling can be explained when surface stabilizer is involved in solid-state 
transformation (i.e. molecular interaction). Accordingly, the stabilizer is not able to protect 
against aggregation. Kayaert et al. [20] have observed similar solid-state transformation 
effects with a different grade of HPMC (HPMC 5 mPa s) and naproxen during spray 
drying but not during wet milling. Although these researchers did not observe solid-state 
transformation under wet milling, this could be a result of the lower viscosity HPMC (5 
mPa s compared to 12-18 mPa s in the current study) and the lower intensity mill used in 
the Kayaert study.  
In the case of naproxen-Tween 80 nano-suspensions (Figure 5.8) milled at both intensities 
(i.e. 2000 or 3200 rpm), no aggregation, chemical degradation or blue shift in FTIR region 
were observed suggesting naproxen remained crystalline during the wet milling process 
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and was therefore stable.  
 
5.6. CONCLUSIONS 
In conclusion, selection of excipient and milling intensity are very crucial for the stability 
of nano-crystalline suspensions during high intensity wet media milling. Any strong 
interaction between the drug and excipient such as hydrogen bonding and ionic interaction 
can lead to instability during the wet milling process via drug solubilization (or 
amorphization) in the excipient mixture. Modulated temperature DSC and FTIR can be 
routinely utilized to investigate potential molecular interactions between the drug and the 
excipients to carefully select appropriate stabilizers for nano-crystalline suspensions. 
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5.7. Tables 
 
Table 5.1. Particle size analysis during media milling of naproxen with Tween 80 determined 
using a Malvern Zetasizer ZS90. 
 
  
Particle size (nm) 
Drug 
concentration 
(% w/v) 
Stabilizer 
concentration 
(% w/v) 
Milling 
speed 
(rpm) 1 hour 2 hour 3 hour 4 hour 
1 0.2 2000 314 318 317 319 
1 0.6 2000 322 318 313 306 
1 0.2 3200 273 270 273 270 
1 0.6 3200 378 324 328 327 
 
 
Table 5.2. Particle size analysis during media milling of naproxen with HPMC E15 stabilizer 
determined using a Malvern Zetasizer ZS90. 
   
Particle size (nm) 
Drug 
concentration 
(% w/v) 
Stabilizer 
concentration 
(% w/v) 
Milling speed 
(rpm) 1 hour 2 hour 3 hour 4 hour 
1 0.2 2000 231.1 202.7 196.2 195.8 
1 0.6 2000 267.6 228.9 211.1 197.1 
1 0.2 3200 207.6 291.4 413.9 645 
1 0.6 3200 210 502.4 502.4 668.5 
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5.8. Figures 
	  
Figure 5.1. The milling profile of naproxen-HPMC E15 nanosuspensions at high milling intensity 
(i.e. 3400 rpm) determined using a Malvern Zetasizer ZS90. 
 
 
Figure 5.2. Appearance of degradation peaks during wet milling of Naproxen-HPMCE15 
nanosuspensions analyzed via HPLC-UV. 
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Figure 5.3A. DSC thermograms of naproxen-Tween 80 formulations. 
 
Figure 5.3B. DSC thermograms of naproxen-HPMC E15 formulations (milled at 3200 rpm). 
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Figure 5.4. A FTIR plot showing the effect of ball milling on naproxen (naproxen carboxyl 
stretching peak ~ 1726 cm-1 after ball milling is shown in the magnified region). 
 
 
Figure 5.5. ATR-FTIR analysis of naproxen-HPMC E15 wet milled samples milled at 3200 rpm. 
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Figure 5.6. ATR-FTIR analysis of naproxen-HPMC E15 wet milled samples milled at 2000 rpm. 
 
 
Figure 5.7. Comparison of ATR-FTIR analysis of naproxen-HPMC E15 wet milled at both 2000 
and 3200 rpm for 4 hours. 
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Figure 5.8. ATR-FTIR analysis of naproxen-Tween 80 wet milled samples milled at 3200 rpm. 
 
 
Figure 5.9. Dry milling of naproxen with or without HPMC E15. 
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Figure 5.10. Powder XRD showing x-ray diffraction pattern of dry milled samples. 
 
 
Figure 5.11. MTDSC showing naproxen crystal melting point depression with an increase in 
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concentration of HPMC E15.  
 
Figure 5.12. LC-MS data showing the presence of a degradation peak at 208 m/z ratio during wet 
milling (A. un-milled and B. wet milled samples of Naproxen-HPMC E15 nanosuspensions). 
 
 
Figure 5.13. Proposed degradation product of naproxen observed during wet milling with HPMC 
E15. 
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Chapter 6 
	  
	  
	  
	  
	  
Optimization and Dissolution Performance of Different Sized Spray-Dried  
Naproxen Nano-Crystals 
	  
	  
	  
	  
	  
Abstract 
	  
	  
The purpose of this study was to investigate the in vitro dissolution performance of the 
different sized spray-dried nano-crystalline powders of naproxen. A DoE approach was 
used to formulate and optimize nano-crystalline suspension. The critical wet milling 
operation parameters were i.e. drug concentration, drug-to-stabilizer ratio, stabilizer type 
(HPMC E15 or Tween 80) and milling intensity. The nano-crystalline suspensions were 
optimized for size and physical stability and then spray-dried to obtain nano-crystalline 
powders. Trehalose and lactose were investigated as spray-drying auxiliary excipients to 
achieve non-aggregating powders. Particle size, DSC and PXRD were utilized for 
characterization of powder formulations. A modified USP apparatus II was utilized to 
determine the in vitro dissolution of powder formulations. The size of the nano-crystalline 
suspensions was dependent on drug concentration and milling intensity. HPMC E15 
containing formulations were better in terms of the spray-dried powder yield compared to 
Tween 80 containing formulations. Trehalose was selected to formulate non-aggregating 
nano-crystalline powders. No polymorphic changes were observed following the wet 
milling and spray-drying processes. Size dependent in vitro dissolution profiles, utilizing a 
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dialysis sac method were obtained for the crystalline powders. 
 
6.1. Introduction 
	  
In the recent decades, high throughput screening (HTS) methodologies and in silico 
approaches have been utilized for the identification of drug candidates with the result that 
most drugs coming of drug discovery have poor aqueous solubility, high hydrophobicity 
and high molecular weight (1-4). It has been estimated that more than 40% of drug 
candidates are poorly soluble. In order for such drug candidates to progress in the drug 
development pipeline, it is essential to improve their aqueous solubility and therefore their 
oral bioavailability.  
Nano-crystalline suspensions offer a great advantage in terms of increasing the dissolution 
rate and/or solubility of poorly soluble drugs (5-8). Pharmaceutical nano-crystalline 
suspensions can be defined as sub-micron colloidal dispersions of discrete drug crystals, 
ranging from 100 to 1000 nm. These nano-sized systems are thermodynamically unstable 
due to higher Gibbs’ free energy (higher surface-to-volume ratio) (9). However, they can 
be kinetically stabilized on pharmaceutically relevant timescales, using stabilizers such as 
small molecule surfactants and/or polymers. According to the Noyes-Whitney equation, 
dissolution rate is directly proportional to surface area. Accordingly, drug crystals with 
smaller size have a higher surface-to-volume ratio and therefore a faster dissolution rate 
(10).  It should be noted that particle size has a great impact on not only the dissolution rate 
but also solubility. As described by the Ostwald-Freundlich (Kelvin) equation, smaller 
crystal size can lead to a higher surface pressure and thus increased drug solubility (11). 
However, the size impact on drug solubility was only observed for drug particles smaller 
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than 100 nm (5, 12). 
Two different approaches are generally utilized to formulate nano-crystalline suspensions 
i.e. bottom-up and top-down (13). For the bottom-up approach, drug crystals are milled 
(preferably wet milling) or passed through channels (such as high pressure 
homogenization) to achieve nano-crystalline suspensions, whereas for the top-down 
approach, drug solutions are precipitated using an anti-solvent or via solvent evaporation 
(such as spray drying) to achieve nano-sized drug crystals.  Nano-crystalline suspensions 
are susceptible to both physical instability (i.e. crystal growth and agglomeration) and 
chemical instability (i.e. drug degradation) compared to solid dosage forms. Accordingly, 
several drying approaches such as spray- and freeze-drying have been employed to obtain 
solid nano-crystalline powders (14-16). 
In this study, a DoE approach has been applied to understand the process of wet milling 
used to achieve nano-crystalline suspensions. In addition, spray drying was utilized to 
achieve a non-aggregating powder formulation. Naproxen, a poorly soluble drug, was 
chosen as the model compound. Two different stabilizer types (i.e. polymeric (HPMC E15) 
and small molecule surfactant (Tween 80) were utilized to formulate the naproxen nano-
crystalline suspensions. Four critical operation parameters of the wet milling process were 
identified: drug concentration, milling intensity, drug-to-stabilizer ratio and type of 
stabilizer. Following optimization of the wet milling process, a spray dryer (Buchi B-290, 
bench-top) was utilized to produce nano-sized crystalline powders. Two different auxiliary 
excipients were used to prevent physical and chemical instabilities (such as aggregation 
and/or degradation) during the spray-drying process. Three different size crystalline 
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powders were obtained and in vitro dissolution testing was performed using our previously 
developed dialysis sac method. This study demonstrated that a systematic approach can be 
used to achieve non-aggregating nano-crystalline powders with high dissolution rate. This 
approach may be applicable to other poorly soluble drugs.	  
	  
	  
	  
	  
6.2. Materials  
	  
Crystalline naproxen was purchased from Fagron  (Fagron, St. Paul, MN). HPMC E15 was 
purchased from Dow Chemical Company (Midland, MI). HPLC grade acetonitrile 
(ACROS chemicals), trifluoroacetic acid and Tween 80 were purchased from Fisher 
Scientific (Pittsburgh, PA). Hermetic pans and lids were purchased from TA instruments. 
Dialysis sacs were purchased from Spectrum Labs  (Spectrum Laboratories, Inc.). 
	  
	  
6.3. Methods 
	  
6.3.1. Preparation of naproxen nano-crystalline suspensions 
Briefly, naproxen was suspended in aqueous stabilizer solution (i.e. HPMC E15 or Tween 
80 solutions), using a magnetic stirrer. The suspensions were stirred for 30 minutes to 
completely wet the drug to obtain macro-suspensions. The prepared macro-suspensions 
were milled using a Netzsch media mill (Netzch, Exton, PA), as described under the DoE 
section below. All suspension formulations were milled for four hours and analyzed for 
particle size and polymorphic changes, if any. The temperature of the mill was maintained 
below 28°C using two cooling bath re-circulators (one attached to the milling chamber and 
the other attached to the suspension re-circulation chamber). 
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6.3.2. Spray drying of nano-crystalline suspensions 
Naproxen nano-crystalline suspension formulations were spray dried using a lab scale 
Buchi spray dryer B-290 (Buchi Labortechhnik AG, Switzerland). Briefly, the spray dryer 
was pre-conditioned using 100 ml of distilled water. Once the spray dryer was equilibrated, 
100 ml of the nano-crystalline suspensions were spray dried using a 0.5 mm spray nozzle. 
All nano-crystalline suspension formulations were spray dried at a feed rate of 7.5 ml/min 
and an inlet temperature of 150°C. Atomizing spray air pressure was kept constant at 40 
mm Hg (approximate air flow 600 l/hour) for all the formulations studied. The dried 
samples were scraped off the collection chamber using a plastic scraper and further 
evaluated for moisture content, particle size as well as crystallinity. 
6.3.3. Particle size analysis 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments). The Z-average (at 90° scattering angle) and the PDI (polydispersity index) of 
the nano-crystalline suspensions were determined. Briefly, the samples were suspended in 
a saturated and filtered (0.2 µm membrane filter) solution of naproxen in 30% glycerin 
solution to avoid any discrepancy arising from drug dissolution during measurement. The 
viscosity of this dispersant solution was measured using a Brookfield viscometer (Model 
DV-III) and utilized in calculating the particle size of re-dispersed or liquid nano-
crystalline suspensions. Each sample was analyzed in triplicate and the results were 
reported as the mean value of the runs. 
6.3.4. Differential scanning calorimeter (DSC) 
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The DSC (TA Q1000 calorimeter) was calibrated using indium and sapphire for 
temperature and enthalpy, respectively. Approximately 5 - 10 mg of spray dried or liquid 
samples were sealed in hermetic pans and analyzed. The heating rate was kept constant at 
5°C/min. Nitrogen at 50 ml/min was used as the purging gas. Data was analyzed using TA 
universal analysis software. 
6.3.5. HPLC-UV analysis 
Naproxen concentration was determined using a Perkin Elmer HPLC system (series 200) 
with a UV absorbance detector (Perkin Elmer) set at 270 nm. The mobile phase was a 
mixture of acetonitrile and 0.1% trifluoroacetic acid (50/50, v/v). A Waters® C18 
symmetry column (4.6 mm×150 mm, 5 µm) was used with 1 ml/min flow rate and the 
column temperature was set at 30°C. The chromatograms were analyzed using PeakSimple 
Software. 
6.3.6. Powder X-ray diffraction (PXRD) 
PXRD was used to determine the crystallinity of the spray-dried samples. X-ray diffraction 
patterns were obtained using an X-ray diffractometer (Model D5005, Bruker AXS Inc., 
Madison, WI) with Cu-kα radiation, a voltage of 40 kV, and a current of 40 mA. All scans 
were performed at a rate of 2°/minute with steps of 0.02° from 5° to 40° 2θ ranges. 
6.3.7. In vitro dissolution testing 
In vitro dissolution testing was performed in USP apparatus II (AT7 smart, Sotax AG, 
Switzerland) using a previously reported dialysis sac method. The spray-dried crystalline 
powders were re-suspended in distilled water and 1 ml of re-suspended suspension was 
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placed inside the dialysis sac. Briefly, dialysis sacs containing crystalline suspension 
formulations were secured in the dissolution chamber (as shown in Figure 1) and in vitro 
dissolution testing was performed. All the dissolution tests were conducted at 37°C in 900 
ml (sink condition) of phosphate buffer (50 mM, pH 6.8) with 50 rpm paddle speed. At 
pre-determined time intervals, 1 ml of sample was withdrawn from the dissolution 
chamber (outside the dialysis sacs) and replenished with 1 ml of fresh phosphate buffer. 
All samples were analyzed using HPLC. 
6.3.8. Design of Experiment (DoE) 
A preliminary study was conducted to identify the critical factors in the media milling 
process and to select the appropriate range of these factors for the DoE study. It was 
observed that milling intensity and drug concentration (drug load) were critical for the 
milling efficiency i.e. rate of particle size reduction. In addition, type of stabilizer and 
drug-to-stabilizer ratio were important for the stability of the nano-crystalline suspensions. 
Based on these preliminary results (data not shown), four critical operation parameters 
were selected: 1) milling speed (rpm); 2) drug concentration (%, w/v); 3) type of stabilizer 
(polymeric versus small molecule); and 4) ratio of drug-to-stabilizer (w/w). The ranges of 
these four critical parameters (Table 6.1) were selected based on successful processing of 
the nano-crystalline suspensions. A full factorial design was utilized to understand the 
process and formulation parameters for particle size reduction. The critical quality 
attributes (CQAs) of the liquid crystalline suspension formulations were: particle size and 
drug crystallinity. As shown in the full factorial design space (Table 6.2), a total of 22 
experiments were performed. All formulations were milled for four hours and every other 
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hour wet milled samples were collected and analyzed. 
 
6.4. Results 
6.4.1.  Wet milling of naproxen nano-crystalline suspensions 
In the case of Tween 80 containing suspension formulations, the drug-to-stabilizer ratio 
had a minimal effect on the particle size of naproxen nano-crystalline suspensions (Figure 
6.1). In addition, an increase in drug concentration from 1% (w/v) to 5% (w/v) resulted in 
decreased size of the nano-crystals during wet milling. Interestingly, the higher milling 
speed resulted in larger nano-crystal size compared with the lower milling speed as shown 
in Figure 6.1. As shown in the contour plots (Figure 6.2), the smallest nano-crystals were 
obtained at the highest drug concentration (i.e. 5% w/v) and the lowest milling speed (i.e. 
2000 rpm) at all drug-to stabilizer ratios studied. 
Similar results were obtained with HPMC E15 (polymeric stabilizer) containing naproxen 
nano-crystalline suspensions. The ratio of drug-to-stabilizer had no or minimal effect on 
the particle size of naproxen nano-crystals (Figure 6.3). Low milling speed (i.e. 2000 rpm) 
and high drug concentration (i.e. 5%, w/v) resulted in small naproxen nano-crystalline 
suspensions (Figures 6.3 and 6.4). As shown in the surface plots (Figure 6.5), the slowest 
milling speed (i.e. 2000 rpm) and the highest drug concentration (i.e. 5%, w/v) resulted in 
the smallest naproxen nano-crystalline suspensions for both small molecule surfactant 
(Tween 80) and large molecular weight polymeric (HPMC E15) stabilizers.  
6.4.2. Optimization and characterization of naproxen nano-crystalline suspensions 
Based on a DoE study, 5% w/v of naproxen (with 0.2% w/v stabilizer concentration) and 
	  
	  
	  
	  
134 
lower milling speed i.e. 2000 rpm were chosen to formulate all the naproxen nano-
crystalline suspension formulations. Milling was performed at these optimized conditions 
and the samples withdrawn during the milling were analyzed for particle size and 
crystallinity. In case of the Tween 80 containing formulations, the particle size remained 
constant after approximately 90 minutes of continuous milling and no further particle size 
reduction was observed (Figure 6.6). In case of the HPMC E15 containing formulations, 
longer milling time was required to achieve small nano-crystals (approximately 240 
minutes) as shown in Figure 6.6. The naproxen nano-crystals prepared with HPMC E15 
were significantly smaller compared to those prepared with Tween 80. In addition, no 
polymorphic changes were observed during the milling process (Figure 6.7A and 6.7B). A 
slight lowering of the naproxen melting temperature was observed with the 
nanosuspension formulations. 
6.4.3. Spray drying to formulate non-aggregating nano-crystalline powders 
Spray drying was utilized to prepare dried powders of naproxen nano-crystalline 
suspensions. It was observed that spray-dried powders could not be obtained for Tween 80 
containing naproxen nano-crystalline formulations. Most of the naproxen nano-crystalline 
powder was stuck on the drying chamber wall of the spray dryer, resulting in very low 
recoveries (less than 5% w/w). Accordingly, HPMC E15 was chosen for spray drying 
processing of the naproxen nano-crystalline suspensions. Based on other literature and our 
previous results, disaccharides (i.e. lactose and trehalose) were utilized to prevent nano-
crystal aggregation during spray drying processing. Two formulations of naproxen-HPMC 
E15 crystalline suspensions were wet milled at drug-to-stabilizer (HPMC E15) ratios of 
1:0.2 (w/w) and 1:0.5 (w/w), respectively. These wet milled formulations were spray dried 
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with either lactose or trehalose at the drug-to-disaccharide ratio of 1:3 w/w. As shown in 
Figure 6.8, disaccharides (bulking agent) can effectively prevent against nano-crystal 
aggregation. Trehalose was selected for naproxen nano-crystalline powder formulations 
(with 0.5% w/v HPMC E15 as stabilizer) since trehalose resulted in a higher yield of 
spray-dried powder compared to lactose. 
6.4.4. In vitro dissolution testing 
Three different sized (i.e. approximately 240 nm, 640 nm and un-milled) naproxen-HPMC 
E15 crystalline suspensions were formulated based on the above DoE and spray drying 
results. All these formulations were characterized for particle size (before and after spray 
drying), moisture content and crystallinity. All the formulations had less than 3% moisture 
content (data not shown) as determined by Karl-Fisher titrimetry. The particle sizes of all 
the liquid and spray-dried formulations are shown in Table 6.3. It was noted that there was 
a slight increase in the particle size and PDI following the spray drying process. No 
polymorphic changes were observed for any of the formulations (Figure 6.9). A previously 
developed dialysis sac method in combination with USP apparatus II, was utilized for in 
vitro dissolution testing of the naproxen crystalline suspensions. The in vitro dissolution 
testing was performed under both acidic (pH 1.2) and neutral conditions (pH 6.8) (Figure 
6.10A and 6.10B). As shown in Figure 13, the dialysis sac method was able to 
discriminate among the different sized naproxen crystalline suspension formulations (i.e. 
milled and un-milled suspensions) at both pH values investigated. 
	  
	  
6.4. Discussion 
It was observed that the smallest nano-crystal formulations were obtained at the lowest 
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milling speed and the highest drug concentrations. Over the concentration range studied 
(1-5% w/v), high drug concentration is expected to increase the number (or frequency) of 
collisions (either among the drug particles or between the drug particles and the zirconia 
beads) and therefore result in smaller sized crystals. Since higher milling speed should 
result in a reduction in particle size, the large particle size observed at 3400 rpm must be a 
result of formulation destabilization and aggregation. The naproxen nano-crystals obtained 
at 2000 rpm using HPMC E15 as the stabilizer were smaller than those prepared using 
Tween 80 as a stabilizer and took a longer milling time to achieve constant particle size 
(Figure 6). This may be due to the higher viscosity of the HPMC E15 solution compared to 
Tween 80. It has been previously reported by Kumar et al. that there is a strong interaction 
between naproxen and HPMC E15. Accordingly, HPMC E15 will provide better surface 
coverage at the nano-crystal surface compared to Tween 80 resulting in smaller crystal size 
(17). The naproxen-Tween 80 formulations could not be successfully spray dried due to 
the powder sticking on the spray dryer walls. This is considered to be a result of the very 
high water solubility and very low melting temperature (Tm) of Tween 80 (approximately 
-20°C). This can be compared to HPMC E15 which has a glass transition temperature of 
approximately 150°C. All the formulations were spray dried at 150°C (inlet temperature) 
and since there is such a large differential between the Tm of Tween 80 and the spray 
drying inlet temperature, Tween 80 will be in a rubbery/melted state resulting in the 
observed stickiness of the formulations. Trehalose containing formulations had better 
yields compared to lactose containing formulations. This is considered to be due to the 
higher Tg of trehalose (114°C) compared to lactose (101°C). As discussed above the lower 
Tg lactose will be more rubbery compared to trehalose and therefore will cause more 
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sticking of the particles to the spray dryer walls. Our previously developed dialysis sac 
adapter in conjunction with USP apparatus II was able to distinguish three crystalline 
naproxen formulations based on their sizes. This study shows the importance of particle 
size on dissolution rate and therefore the importance of the nano-sized formulation to 
enhance dissolution. 
 
6.5. Conclusions 
A DoE approach was utilized to understand the process and optimization of wet milling of 
naproxen nano-crystalline suspensions followed by spray drying. The milling intensity and 
the drug concentration were the most critical factors to achieve stable nano-crystalline 
formulations. Small sized nano-crystals were obtained with slow milling speed and high 
drug concentration. The ratio of drug-to-stabilizer had no or minimal impact on size under 
the ranges investigated. Nano-crystal aggregation was observed at the highest milling 
speed i.e. 3200. The size of the HPMC E15 containing nano-crystalline suspension was 
smaller compared to Tween 80 formulations, which may be due to the better surface 
coverage provided by HPMC E15. In addition, it was not possible to spray dry the Tween 
80 containing formulations due to the low melting temperature of Tween 80, which 
resulted in particle aggregation and sticking to the spray dryer walls. Three different sized 
(wet milling and un-milled) formulations were optimized and spray drying was performed 
to achieve non-aggregating crystalline formulations. A discriminatory dissolution method 
was developed to distinguish crystalline formulations based on their size. This method can 
be utilized for the testing of other dosage forms such as microspheres, liposomes, 
emulsions etc. 
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6.6 Tables 
 
Table 6.1. Critical operation parameters for wet media milling. 
Critical parameters Levels 
Milling speed/intensity (rpm) 2000 (low), 2700 and 3400 (high) 
Drug concentration (% w/v) 1 (low), 3 and 5 (high) 
Type of stabilizer 
HPMC-E15 (high molecular weight polymer) and 
Tween-80 (small molecule surfactant) 
Ratio of drug-to-stabilizer 
(w/w) 
1:0.2 (low), 1:0.4 and 1:0.6 (high) 
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Table 6.2. Full factorial design space and particle size following wet milling processing. 
Run 
Order 
Type of 
stabilizer 
Conc. of 
drug 
Ratio of 
drug to 
stabilizer 
Milling 
intensity 
(rpm) 
Z average 
(nm) PDI 
1 Tween 80 1 0.6 3400 327 0.25 
2 HPMC 1 0.6 3400 645 0.21 
3 HPMC 3 0.4 2700 215.5 0.14 
4 HPMC 5 0.2 3400 299.8 0.08 
5 HPMC 5 0.2 2000 201 0.09 
6 HPMC 5 0.6 3400 283.5 0.12 
7 Tween 80 5 0.6 3400 292.4 0.14 
8 HPMC 1 0.2 2000 195.8 0.11 
9 HPMC 1 0.6 2000 197.1 0.13 
10 Tween 80 3 0.4 2700 281.6 0.20 
11 Tween 80 3 0.4 2700 288.4 0.22 
12 Tween 80 1 0.6 2000 306.7 0.31 
13 Tween 80 5 0.2 2000 230.8 0.16 
14 Tween 80 1 0.2 2000 319.4 0.20 
15 HPMC 5 0.6 2000 263.7 0.12 
16 Tween 80 5 0.2 3400 270.3 0.18 
17 Tween 80 5 0.6 2000 251 0.19 
18 Tween 80 3 0.4 2700 300.5 0.20 
19 HPMC 3 0.4 2700 307.1 0.16 
20 Tween 80 1 0.2 3400 328.9 0.27 
21 HPMC 3 0.4 2700 252.4 0.13 
22 HPMC 1 0.2 3400 668.5 0.27 
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Table 6.3: Particle size measurement (intensity average) before and after spray drying of naproxen 
crystalline suspensions. 
 Particle size (nm) PDI (nm) 
Formulations Before SD After SD Before SD After SD 
Nano-crystalline 
formulation (~ 240 
minutes milled) 
243.3 282.0 77.8 114 
Milled formulation 
(~2 minutes) 641.7 664.2 265 327.4 
Un-milled 
formulation n/a n/a n/a n/a 
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6.7. Figures 
 
 
Figure 6.1. A plot showing the effect of the critical operation factors on the particle size of 
naproxen nano-crystals using Tween 80 as a stabilizer. 
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Figure 6.2. Contour plots showing the effect of milling speed and drug concentration on the 
particle size (nm) of naproxen nano-crystals with Tween 80 (top: drug-to-stabilizer ratio of 1:0.2 
and bottom: drug-to-stabilizer ratio of 1:0.6). 
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Figure 6.3. A plot showing the effect of the critical factors on the particle size of naproxen nano-
crystals using HPMC E15 as a stabilizer. 
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Figure 6.4. Contour plots showing the effects of milling speed and drug concentration on the 
particle size (nm) of naproxen nano-crystals with HPMC-E15 (top: drug-to-stabilizer ratio of 1:0.2 
and bottom: drug-to-stabilizer ratio of 1:0.6). 
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Figure 6.5. 3D surface plots showing the effect of drug concentration and milling speed on particle 
size reduction of naproxen crystalline suspensions after 4 hours of continuous milling (top: Tween 
80 as a stabilizer and bottom: HPMC E15 as a stabilizer). 
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Figure 6.6. A plot showing size reduction during wet media milling at optimized conditions (i.e. 
2000 rpm and 5% w/v drug concentration) using different stabilizers (i.e. Tween 80 and 
HPMCE15). 
	  
 
Figure 6.7A. DSC thermogram showing the effect of milling time on the crystallinity of naproxen 
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suspensions using Tween 80 as a stabilizer. 
	  
	  
 
Figure 6.7B. DSC thermogram showing the effect of milling time on the crystallinity of naproxen 
suspensions using HPMC E15 as a stabilizer. 
	  
	  
	  
 
Figure 6.8. A plot showing the effect of auxiliary excipients (or bulking agent) on nano-crystal 
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aggregation following spray-drying processing. 
	  
	  
	  
Figure 6.9: Powder X-Ray diffraction of spray dried naproxen crystalline powders. 
	  
	  
 
Figure 6.10A. In vitro dissolution profiles of spray dried naproxen crystalline formulations (re-
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suspended liquid form) in 50 mM phosphate buffer (pH 6.8). 
 
	  
 
Figure 6.10B. In vitro dissolution profiles of spray dried naproxen crystalline suspensions (re-
suspended liquid form) in 0.1N HCl (pH 1.2). 
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Chapter 7 
	  
	  
	  
Conclusions and Future Studies 
	  
	  
	  
7.1. Summary and conclusions 
In recent years, the number of poorly soluble drug entities (Biopharmaceutics 
Classification System, BCS class II/IV) coming out of drug discovery has increased 
significantly. Nano-crystalline suspension is one of the commonly utilized approaches to 
increase the dissolution rate and hence oral bioavailability of poorly soluble drugs. One of 
the major challenges with formulation of nano-crystalline suspensions is the preservation 
of their physical and chemical stability in aqueous medium (i.e. distilled water).  
Nanosuspensions are susceptible to both physical instability (crystal growth and 
agglomeration) and chemical instability (degradation) compared to solids. Spray and 
freeze-drying of nano-crystalline suspensions are preferred but not many exhaustive 
studies are available to understand the process of drying. Hence, the goal of this research 
was to provide critical information on: 1) effect of critical drying formulation and process 
variables on the performance of nano-crystalline powders, and 2) understand the effect of 
wet milling in combination with spray drying on the stability of dried powder of nano-
crystalline formulations. 
 
The effect of spray drying processing variables of nano-crystalline suspensions was 
investigated. It was observed, that formulations dried at higher temperatures had less 
moisture content compared to formulations dried at lower temperatures. The 
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nanosuspension percent yield was mainly dependent on the flow and aspiration rates. The 
inlet temperature was identified as the only critical parameter (p value <0.05) affecting 
particle aggregation during nanosuspension spray drying due to crystal melting or 
amorphization at or above the melting temperature (indomethacin melting temperature 
158°C). Particle aggregation increased with increasing temperature due to surface 
amorphization/crystal defects that lead to unstable formulations. Accordingly, It was 
concluded that spray drying of nano-crystalline suspensions should be performed below 
the drug melting temperature with high flow and aspiration rates for maximum recovery 
with minimal nano-crystal aggregation. 
 
After optimization of spray drying processing variables, the effect of nano-crystalline 
formulation variables were investigated during spray drying. A DoE approach was utilized 
to understand the critical formulation variables. The aggregation tendency of spray-dried 
nano-crystal powders showed a dependency on the drug-to-stabilizer ratio. The nanocrystal 
yield during spray drying showed dependency on all factors studied i.e. drug, excipient, 
drug to stabilizer ratio and drug concentration. The Tg and charge of the formulation 
played a dominant role during the spray drying process. In addition, we have applied chi 
(χ) interaction parameter to the stability of polymer-stabilized nano-sized systems (i.e. 
nanocrystalline formulations). The stability of the spray-dried powder correlated with the 
interaction parameter (calculated using the melting point depression approach) between the 
drugs (i.e. naproxen and indomethacin) and HPMC E15 (high molecular weight polymer). 
A dissolution method utilizing dialysis sacs with USP apparatus II was able to distinguish 
aggregated versus non-aggregated nano-sized formulations. 
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After spray drying process and formulation optimization, the effect of matrix formers or 
bulking agents was investigated on nano-crystal aggregation. All the formulations 
containing small molecular weight bulking agents were non-aggregating compared to those 
formulations containing polysaccharides during spray or freeze-drying processing of 
indomethacin nano-crystalline suspensions. In addition, higher crystalline powder yields 
were observed with formulations containing higher glass transition temperature bulking 
agents during spray drying. The bulking agents with low glass transition temperatures were 
sticking to the spray drier glass walls and thus resulted in lower yields. The small 
molecular weight bulking agents showed favourable or strong interactions with Dowfax 
2A1 (via IR and contact angle) and this may be the reason for no or minimal nano-crystal 
aggregation during spray or freeze drying. A combination of bulking agent (i.e. small 
molecular weight and polysaccharides) may be utilized to achieve higher spray-drying 
yields and non-aggregating nano-crystalline powders.   
In addition, the effect to high intensity wet milling on the physical and chemical stability 
of a poorly soluble drug was investigated. Wet milling of naproxen-HPMC E15 at high 
milling intensity caused both physical and chemical instabilities as observed by particle 
size measurement and chemical analysis, respectively. The naproxen-Tween 80 
formulations were stable regardless of milling intensity. Naproxen-HPMC E15 wet-milled 
samples, showed an IR peak shift suggesting strong bond formation or molecular 
interaction (i.e. amorphous phase). In addition, naproxen has a strong interaction with 
HPMC E15 as determined by Modulated temperature DSC (i.e. melting point depression). 
The generation of amorphous phase at the naproxen-HPMC E15 crystal surface may be 
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responsible for both aggregation and degradation during wet milling. Decarboxylated 
naproxen was identified as a degradation product. Milling intensity and/or selection of 
stabilizer/s are crucial for the stability of nano-crystalline suspensions.  
The QbD (or specifically DoE) studies performed in this research are examples of how this 
approach can be used to obtain design space for spray-dried nano-crystalline powders of 
poorly soluble drugs. In addition, the selection criteria utilizing DSC (i.e. melting point 
depression approach) can be utilized for stabilizer/s selection for nano-crystalline 
suspension formulation as well during spray drying processing. From an industrial 
perspective, this study provides an in-depth understanding of the parameters involved in 
nano-crystalline formulation and processing via wet milling and spray drying.  
 
7.2. Future studies 
Further investigation should be performed to fully understand the interaction between 
bulking agents and stabilizers. In particular, Raman, IR and AFM microscopy can be 
performed to evaluate the distribution of drug crystals within the stabilizer matrix. In 
addition, ss-NMR can be utilized to understand the interaction between them. 
The developed spray-dried nano-crystalline formulations were superior in their dissolution 
performance compared to the un-milled formulation. In addition, in vivo studies should be 
performed in combination with in vitro dissolution, to evaluate and perform IVIVC for the 
spray-dried nano-crystalline powders.  
 
